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Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the number one killer due to 
a single infectious agent. Although, there is a vaccine against TB and antimicrobial treatments 
available, approximately 1.8 million people die each year. This underlines the importance of 
identifying and understanding mediators of TB pathogenesis to develop new diagnostics for early 
detection and therapies to treat individuals progressing to active disease. One of the cellular 
mediators that may play a role in TB pathogenesis are neutrophils. Neutrophils have been 
associated with active Tuberculosis (ATB); however, the role that neutrophils play 
within Mtb infection and disease is still unknown. To further understand the role that neutrophils 
play within TB pathogenesis, neutrophils were depleted in the acute and chronic stages of 
infection. Neutrophil depletion did not impact susceptibility during acute stages; however, 
susceptibility was significantly decreased during chronic stages. This suggests neutrophils 
promote Mtb infection and pathogenesis during the chronic stage of infection. This body of work 
demonstrates that decreasing neutrophil accumulation in the lung and promoting host protection 
can be mediated through neutrophil proteins, such as S100A8/A9, as well as TGF-β, an anti-
inflammatory cytokine. Results demonstrate that S100A8/A9 promotes chronic increases 
 vii 
susceptibility and may be mediated through CD11b dependent lung neutrophil accumulation and 
Mtb uptake. While not a neutrophilic protein, TGF-β inhibition significantly decreases 
susceptibility and neutrophil accumulation as chronic disease progressed. Overall, these results 
provide evidence that S100A8/A9 and TGF-β contribute to neutrophil mediated accumulation 






































Introduction to tuberculosis and neutrophils 
1.1 TB: A Global Burden 
Mycobacterium tuberculosis (Mtb), an intracellular bacterium, is implicated as the causative agent 
of the disease tuberculosis (TB). Approximately one fourth of the world's population (1.3 billion 
people) is latently infected with Mtb (1, 2).  Roughly 10% of infected individuals can progress 
towards active TB (ATB) disease. While the overall TB incidence is decreasing at an approximate 
rate of 2% each year, there is still a quarter of the world’s population who are at risk of progressing 
to active disease (2). The majority of infected-individuals are diagnosed and treated for ATB; 
however, an estimated 5.6 million infected individuals are believed to be undiagnosed by the 
current limitations of the diagnostic tests and are therefore left untreated, posing a risk for disease 
spread. Despite the use of M. bovis Bacillus Calmette–Guérin (BCG) as a preventative vaccine, 
TB continues to cause 1.3 million deaths each year (2).  According to the World Health 
Organization (WHO), identification of new treatment strategies that decreases latently infected 
individuals from progressing to ATB and development of rapid diagnostic testing is of priority, 
along with the generation of an effective TB vaccine (2). In order to meet these goals, it is 
necessary to understand immune responses that provide humans with protection against Mtb 
infection. Thus, research directed towards deciphering the protective host immune mechanisms 
and identification of biomarkers of protection are critical for effective translational applications 
including developing novel therapeutics and reliable diagnostics.  
1.2 TB Disease Outcomes  
TB is spread to others through the inhalation of Mtb laden aerosols. Once inhaled, Mtb is able to 
replicate and localize and/or disseminate from the lungs (3). The dynamic disease spectrum of 
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Mtb infection is continuous and best characterized as follows: clearance, latency, reactivation 
and active status. Host response plays an essential part in determining whether an individual is 
able to effectively clear the infection, control the infection or progress to active disease states. 
The innate and adaptive host immune responses are able to influence each of these outcomes. 
Alveolar macrophages and neutrophils have been suggested to be important for influencing early 
control and clearance (4-9). For the adaptive immune response, T cells and IFN-γ production 
have been important for Mtb control (10, 11).  Granulomas, a hallmark characteristic of TB, are 
thought to be protective and functions to confine Mtb growth and prevent Mtb spread. Although 
granulomas can be an indicator of protection, granulomas can promote pathogenesis by creating 
an environment favorable for Mtb growth (12, 13).  Similar to the outcomes of TB, granuloma 
formation, organization and its ability to control Mtb can promote pathogenesis or protection 
depending on the immune cellular responses and composition. 
1.2.1 Mtb Clearance 
Individuals exposed to Mtb but are capable of successfully clearing the pathogen may not have a 
positive tuberculin skin test (TST) or interferon-γ release assay (IGRA) results(14-17). Early 
clearance can be denoted as individuals who have cleared Mtb before the successful mounting of 
an adaptive immune response (18). Although there are several innate cellular populations, 
alveolar macrophages and neutrophils have been implicated in protection and disease 
progression (4, 19-21). It has been suggested that alveolar macrophages may play a role in early 
clearance (4, 22). Upon infection alveolar macrophages are amongst the first cells to recognize 
and respond to Mtb by producing pro-inflammatory cytokine and chemokines as well as 
secreting antimicrobial peptides (4, 7-9, 22, 23). Neutrophils and their cell specific proteins also 
contribute to effective Mtb killing (5, 6). Thus, an effective host innate immune response is 
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capable of controlling Mtb growth and the progression of TB disease. In addition to innate 
immunity, the adaptive immune response, especially IgM antibodies have been implicated in 
“resisting” progression to latent disease in individuals who are highly exposed to Mtb (24). In a 
recent 2019 study, a cohort of Ugandan individuals who were highly exposed to Mtb, yet were 
not positive for TB (via TST and IGRA), possessed IgG and IgM antibodies against Mtb proteins 
and IFN-γ independent T cell responses (24). Mtb clearance has been shown to be dependent and 
independent of the innate and adaptive immune response. Further research needs to continue to 
elucidate the mechanisms that promote and enhance Mtb clearance. 
1.2.2 Latent TB 
Individuals who have untreated active TB (ATB) are the source for transmitting aerosols to 
uninfected and susceptible individuals, thus increasing individuals that can become latently 
infected (25). Those who are latently infected (LTBI) are classified as having T-cells that are 
sensitized to Mtb antigens and do not have clinical signs and symptoms (3). T-cell sensitization is 
measured using the TST or IGRAs (3). Quantiferon-TB Gold, an IGRA in vitro blood assay, tests 
an individual’s sensitization to Mtb antigens like early secretory antigen target-6 (ESAT-6), culture 
filtrate protein 10 (CFP-10) amongst others (26). Even though these tests are valuable at 
determining those who have been exposed to Mtb, they are unable to determine if the infection is 
prior, persistent or static.  Low neutrophil blood counts are associated with IGRA positivity status 
in TB contacts -indicating neutrophils may have a role in control or pathogenesis (6). Historically, 
latency has been thought to be due to entrapment of Mtb within granulomas, decreased Mtb 
metabolism and Mtb replication (27). Although it is possible to identify individuals that are latently 
infected, it is important to screen those who would most likely progress to active disease and treat 
them prophylactically with anti-TB therapeutics. 
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1.2.3 Reactivation and Active Infection 
Latently infected individuals have a 5 to 10% risk of reactivating and progressing to active disease 
(28). Reactivation may be associated with Mtb strains (geographically located) and disease severity 
at the time of diagnosis (29, 30). In the case of latency, the immune system mounts a robust 
response to contain the infection and Mtb prevents itself from being cleared. However, when the 
immune response is not sufficient in controlling the infection, reactivation occurs (31). 
Additionally, Mtb coinfection with HIV increases an individual’s risk of developing TB by 26-31 
times (32). Diabetes, a comorbity often associated with TB, enhances an individual’s risk of 
developing TB by three times (32). Even though loss or overabundance of protective immune 
responses, such as the production of TNF-α and anti- TNF-α immunotherapy, has been shown to 
increase bacterial burden and negatively impact granuloma structure and pathology, it has also 
been demonstrated to lead to reactivation (33-38). Although there are multiple animal models that 
aid in understanding mechanisms of reactivation, the NHP model is the gold standard.  The NHP 
model is considered as the gold standard because NHPs are susceptible to the same Mtb strains 
that cause human pathogenesis, exhibit similar clinical signs, symptoms and histopathology, able 
to embody TB disease outcomes, have similar triggers needed for human Mtb reactivation, are 
genetically diverse and have similar immune responses as humans (39, 40). Although mice have 
similar immunological responses to humans and NHPs, the mouse model typically assesses Mtb 
persistence instead of reactivation. The Cornell model, a mouse model of persistent infection, 
treats Mtb infected mice with anti-mycobacterial drugs to undetectable levels and allows the 
growth of persistent Mtb to spontaneously occur (41).  
Tuberculosis can be generally characterized by three phases – subclinical, prediagnostic and 
clinical (42). The subclinical phase is composed of individuals who may be TST or IGRA negative 
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but have positive bacterial cultures and lack symptoms (42-44). Whereas, individuals in the pre-
diagnostic phase have symptoms but do not seek medical attention and treatment. The clinical 
phase is where individuals have symptoms and seek treatment (42). Although each of these phases 
has distinct differences, TB disease progression continues through each of these phases. The innate 
and adaptive immune responses aim to mount a sufficient response to control Mtb growth and 
infection. Macrophages (innate immune cell) first aim to control Mtb infection by phagocytosing 
Mtb directly or indirectly via other Mtb infected cells (e.g. neutrophils), and processing Mtb 
antigens. If the macrophage is unable to kill Mtb, Mtb replicates resulting in the death of the 
macrophage. Dendritic cells (innate immune cell) are a bridge between the innate and adaptive 
immune system because they are able to phagocytose Mtb and traffic them to a T cell rich lymph 
node where T cells (adaptive immune cell) recognize bacterial antigens and initiates the adaptive 
immune response (45). Once T cells recognize Mtb antigens, they proliferate and migrate from the 
lymph node to the lungs by activating macrophages to kill Mtb using T-cell specific cytokines (e.g. 
IFN-γ and TNF-α) (35, 46-49). The arrival of CD4+ and CD8+ T cells capable of producing and 
secreting IFN-γ, correlates with ATB  (12, 50, 51). Both, IFN-γ and TNF-α, have been 
demonstrated to be important in the control of TB by human and mice studies that show 
deficiencies in IFN-γ and TNF-α production as well as T cells increase TB susceptibility, promotes 
Mtb growth and impacts granuloma formation (35, 46, 50-52).  
1.2.4 Animal models of TB disease 
Animal models are widely used to study TB disease pathogenesis and disease outcome (53). 
Clinical signs, systemic bacterial burden, disease progression and protective/pathological immune 
factors are some of the features animal models help elucidate (53). The most common animal 
models of TB are mice, guinea pigs, rabbits and non-human primates (53). The ease of genetic 
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manipulation, cost and availability of humanized mice makes the mouse model of TB disease 
particularly good to assess anti-TB chemotherapy treatments and understand mediators of 
protection and pathogenesis (54-59). Due to their susceptibility to aerosolized Mtb and the ability 
to form human-like granulomas guinea pigs are good models to assess the efficacy of vaccines 
(53, 60). Similar to guinea pigs, NHPs also are susceptible to Mtb and are able to form humanized 
granulomas, but NHPs are a great model because they are able to undergo wide spectrum of 
diseases - latent, active, reactivation, and clearance, which has not been observed in guinea pigs 
(61). Thus, making NHPs a good model for understanding mechanisms of disease, assessing the 
efficacy of anti-TB treatments and vaccines (62-65). In this work, I have used the NHP and mouse 
models of Mtb-infection to further determine how neutrophils impact Mtb infection and TB 
disease.  
1.3 Innate immune response 
The immune system is made up of two arms namely the innate and adaptive arms that are able to 
respond to pathogens invading the host. Innate immune cells, macrophages, neutrophils and 
dendritic cells, has been implemented in providing protection against contracting Mtb and 
preventing active disease conversion (18, 66). Before the adaptive immune response is activated, 
the innate immune system responds to Mtb. Mtb is recognized by pattern recognition receptors 
(PRRs) (e.g. TLR2, TLR4, DC-SIGN, etc.) expressed on macrophages, dendritic cells (DC), 
neutrophils and natural killer (NK) cells leading to the release of pro-inflammatory chemokines, 
cytokines (e.g. IL-6, IL-1β, and TNF-α), and damage associated molecular patterns (DAMPs) (67-
70). The initiation of this response results in alveolar macrophages, neutrophils, recruited 
macrophages and DCs migrating towards the lung site of infection to aim to kill Mtb, initiate 
granuloma formation to contain Mtb and promote the mounting of an adaptive immune response 
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(70). Although, the adaptive response is important to controlling Mtb, the innate response is 
necessary to prime the adaptive response (70). One of the main components of granulomas and an 
immune cell play within TB is the macrophage. 
Macrophages play a significant role in Mtb pathogenesis because Mtb has been shown to infect 
this population during both early and chronic infection (71, 72). Macrophages have the ability to 
limit Mtb growth through the production of reactive oxygen species (ROS), cytokines and 
phagolysosome maturation as well as other cellular processes. Mtb growth and control is mitigated 
in macrophages when Mtb is able to evade phagosome maturation and lysosomal degradation (73). 
Studies have shown that receptors, specifically the mannose receptor, which recognize Mtb can 
impair phagosome maturation resulting in the survival of Mtb in the macrophage cellular 
environment (74, 75). When Mtb is unable to prevent phagosome maturation, it is localized within 
the phagolysosome compartment. The phagolysosome compartment is an acidic and nutrient 
deficient environment filled with anti-microbial peptides to limit Mtb growth (76, 77). During this 
maturation process, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is recruited 
and assembled to generate ROS (78, 79). ROS has been shown to limit growth in Mtb mutant 
strains deficient in sodA and katG (enzymes that counteract ROS effects) (80). Macrophages are 
able to produce cytokines, such as IL-1β, TNF-α, and IL-12, which have been demonstrated in 
human and mouse studies to contribute to Mtb control (81-84).  
While macrophages are able to sense Mtb, respond to an infection and kill Mtb, dendritic cells 
(DCs) are able to prime the adaptive response through antigen presentation. DC-specific ICAM-
grabbing non-integrin (DC-SIGN), Dectin-1, TLRs and Nod-like receptors are receptors expressed 
on DCs, that are able to recognize Mtb (85-90). After the recognition of Mtb, DCs are able to 
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process its antigens, migrate to the lymph nodes, and present them to, prime and activate T cells 
(91, 92). This priming of T cells by DCs initiates the specific adaptive response driven by T cells. 
After alveolar macrophages recognize and respond to Mtb, neutrophils migrate to the lung and 
respond by releasing DAMPs (e.g. S100A8/A9), neutrophilic proteins (e.g. myeloperoxidase 
(MPO) and elastase) and chemokines and cytokines (93-95). The release of some of these proteins 
has led to Mtb control (96). Unfortunately, by responding to Mtb infection, neutrophils are also 
able to promote immunopathology within the lung (97). Although, many studies have focused on 
the cells of the innate immune system that contribute to Mtb infection, disease and pathology, the 
role that neutrophils play in TB immunopathology is just beginning to be delineated. This thesis 
will mainly focus on the role that neutrophils perform TB pathogenesis.  
1.4 Introduction to neutrophils 
Neutrophils, also known as polymorphonuclear leukocytes (PMNs), are innate immune cells and 
are cellular components of the inflammatory immune response (98).  The immune system is 
capable of inducing an inflammatory response that aids in responding to pathogens (70, 99). 
Although, neutrophils are associated with homeostasis and pathogen clearance, they are also 
associated with inflammatory diseases, such as acute lung injury, chronic obstructive pulmonary 
disease (COPD) and arthritis (100-103). They are short lived and are the most abundant 
leukocyte in the blood (104-106). They are characterized by the presence of granules in the 
cytoplasm and their nuclear structure. Neutrophils are able to develop and mature in the bone 
marrow and migrate and respond to infections throughout the body.  
1.4.1 Neutrophil migration 
Neutrophils are derived from myeloid precursors in the bone marrow through the process of 
granulopoiesis (70, 99). Neutrophils are produced and matured within the bone marrow from 
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myeloid lineage progenitor cells, specifically common myeloid progenitor cells (CMPs) (99).  
Eventually CMPs differentiate to become a granulocyte macrophage progenitor cell (GMP) (107-
110). Maturation in humans takes approximately 5-6 days; whereas, 2-3 days in rodents (111-113). 
Upon maturation, they are released and make up approximately 50-70% of leukocytes in 
circulation (105, 112, 114). Once in circulation, neutrophils are able to migrate towards sites of 
infection and respond to microbial pathogens (115). There are two neutrophil pools within the 
vasculature – an intravascular blood and tissue specific pool (104, 116-118). Intravascular blood 
and vasculature neutrophils are different due to changes in the cytoskeleton and actin formation 
(119). Neutrophil migration from the bone marrow into the blood is largely affected by actin 
cytoskeleton rearrangement (120). Cytoskeleton rearrangement is critical to the migration of 
neutrophils on endothelial surfaces, which is mediated through selectins (e.g. P-selectin) and 
integrins (e.g. LFA-1 and Mac-1) expressed on neutrophils that bind to the endothelium adhesion 
molecules (e.g. ICAM-1) (120-122). This selectin mediated interactions allows for neutrophil to 
migrate across the vascular endothelial surface. CXCR4 is an important chemokine receptor 
needed in mice and primates for neutrophils to migrate to the lung (104, 123). There are studies 
that suggest that the lung has a resting population of neutrophils that may be used during a need 
for rapid mobilization (104). Under homeostatic conditions, neutrophils undergo apoptosis and are 
removed by mononuclear phagocytes (e.g. macrophages) or return to the bone marrow via a 
CXCR4-dependent mechanism for clearance (115, 124-126).  
1.4.2 General neutrophil responses 
After migrating to a site of infection, neutrophils have several mechanisms of recognizing and 
responding to pathogens. Neutrophils are able to respond to infection via: 1) phagocytosis, 2) 
degranulation, 3) deploying neutrophil extracellular traps (NETs), and producing chemokines and 
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cytokines (127, 128). Neutrophils are able to recognize and phagocytose microbes via Fc-γ, 
complement receptors and toll-like receptors (TLRs) (70, 115, 129, 130). Neutrophil pathogen 
recognition and phagocytosis induces changes in cellular surface receptors and molecules, 
generates ROS and causes the degranulation of antimicrobial peptides and enzymes. Generally, 
when pathogens fuse to neutrophil phagosomes they are either fused with granules that contain 
antimicrobial peptides and proteases, initiate NADPH-oxidase to produce superoxide anions, 
hydrogen peroxide, and ROS (70, 99, 115). In addition to their phagocytosis abilities, they also 
use defense mechanisms such as traps NETs (70, 115, 121, 122, 127, 131). NETs aid in 
immobilizing and killing microbes by releasing chromatin fibers from the nucleus that also contain 
granules rich in antimicrobial proteins (132-134). Often times, antimicrobial peptides and 
proteases are also damaging to the host by inducing inflammation and tissue damage (115). 
Neutrophil activation and priming is highly modulated through cytokines, chemokines and growth 
factors, such as pathogen associated molecular patterns (PAMPs), TNF-α, IFN-γ (70, 115, 135).   
1.5 Neutrophils and tuberculosis 
1.5.1 Neutrophil studies and other models 
Human and murine neutrophils have differences that may play a role in the interpretation of 
experimental data. As stated above, maturation rates are different as well as the percentage of 
neutrophils in the blood, morphology, granule components, chemokine and chemokine receptor 
expression, as well as surface marker expression are different in humans versus murine systems 
(99, 136-139). Studies to determine the role of neutrophils during Mtb infection have been done in 
various animal models (e.g. rats, guinea pigs, zebrafish, etc.).  Neutrophils have been described 
and defined based on characteristics, such as cell-surface markers, functions, localization and 
maturity in both healthy and infected individuals (Silvestre-Roig C 2019). Staphylococcus aureus 
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and Candida albicans studies have shown that neutrophil subpopulations are present during 
infection that are either proinflammatory (CD11b-CD49d+IL-12+) or anti-inflammatory 
(CD11b+CD49d-IL-10+) (140).  Most studies have been done with human peripheral neutrophils, 
which are at their resting stage (137). This can present disadvantages for understanding the 
functional aspects of neutrophils during infection. One difference is that neutrophil surface 
phenotype and functional activity depends on the genetic background of the model studied – mouse 
or human. When taking human neutrophils genetically heterogeneous populations as well has large 
sample sizes need to be considered.  
1.5.2 Impact of neutrophils on TB infection and disease 
As noted in literature, neutrophils are activated to respond to TB infection and disease, but their 
definitive role within Mtb infection is currently unclear and controversial. As with most bacterial 
infections, neutrophils are the first immune cells recruited to the lung during Mtb infection (22, 
115, 141-143). Neutrophil recruitment during the acute phase typically subside in pulmonary TB 
(PTB) contacts after 6 weeks (6). This indicates that there is an acute inflammatory response that 
occurs in response to Mtb infection (6). The roles of neutrophils are controversial because many 
studies provide evidence that indicate neutrophils can contribute to both protection and pathology 
within Mtb infection and disease.  The caveat to these studies is that the RB6-8C5 antibody 
depletes or reduces the number of cells expressing the Gr-1 (Ly6G/Ly6C) cellular marker, which 
includes neutrophils, plasmactoid dendritic cells, monocytes and CD8+ T cells; thereby, making 
it unclear whether neutrophils are protective during Mtb infection. To determine if neutrophils 
impacted Mtb infection, studies have used RB6-8C5 depleting antibody, which depletes 
neutrophils, to transiently deplete neutrophils during early stages of Mtb infection. RB6-8C5 
neutrophil depletion during early Mtb infection increased bacterial burden. This finding suggested 
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that neutrophils are beneficial during Mtb infection (20, 144, 145). To rectify the ambiguity of 
whether neutrophils are protective during Mtb infection, two studies used 1A8 (Ly6G), a 
neutrophil specific antibody to deplete neutrophils during early Mtb infection. Both studies showed 
no difference in bacterial burden (142, 143). However, the study by Blomgran and colleagues 
indicated neutrophils play an indirect role in immune function by demonstrating that when 
neutrophils are depleted dendritic cell migration to the local lymph node decreases and delays in 
the adaptive response occur by decreasing Mtb antigen specific CD4+ T cell proliferation and 
activation. CD4+ T cell lung proliferation and activation due to the lack of neutrophils was also 
shown in the Kang et al. study (143). The two previous studies specifically depleted neutrophils 
and demonstrate the impact of neutrophils; however, both used lab adapted Mtb strains. In addition 
to lab strains, hypervirulent (capable of increased levels of resistance to drugs, increased 
pathogenesis and transmissibility) Mtb strains are emerging which may provide to be more 
informative in investigating the protective or pathological contributions of neutrophils during Mtb 
infection and disease (146-149).  
1.5.3 Neutrophil Mechanisms in TB  
One of the primary effector functions of neutrophils in response to a bacterial infection is to 
phagocytose bacteria. Neutrophils express pattern recognition receptors (PRRs), such as TLRs, C-
type lectins, Fcγ and complement receptors to aid in survey, recognize and respond to Mtb and 
other pathogen invaders (70, 115, 130, 150). When localized in the lung, TLR2, 4 and 9 recognize 
and phagocytose Mtb (71, 151-153). Fc receptors, FcγRII, FcγRIIIb and FcγR1, in addition to 
complement receptors are also present on neutrophils and are highly expressed in neutrophils of 
TB infected individuals (130, 154). Several studies have shown that neutrophils phagocytose Mtb 
(5, 155, 156). Studies have shown that after neutrophils recognize and phagocytose Mtb, they 
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undergo neutrophil apoptosis as a mechanism of controlling Mtb growth (115, 157).  When a 
neutrophil undergoes apoptosis, they have decreased cell function, and reduced antimicrobial and 
pro-inflammatory capacities (115, 158, 159). Mtb has been known to mediate neutrophil apoptosis 
by activating caspase-1,3 and decreasing FcγR1 surface expression (115, 160-162). 
Proinflammatory molecules that prolong neutrophil survival typically prime neutrophils for 
enhanced function (115). Apoptotic neutrophils have been shown to aid indirectly in killing Mtb 
via activated macrophage phagocytosis (96). Tan et. al. demonstrated that the addition of apoptotic 
neutrophils to Mtb infected alveolar macrophages resulted in increased antimicrobial activity (96).  
Neutrophils are able to secrete cytokines and chemokines (e.g. IL-6, CXCL-1, CXCL-10) that are 
able to recruit more neutrophils or enhance the innate immune response to microbes (163). Upon 
observing whether neutrophil infiltration associated with susceptibility, Eruslanov et al. 
demonstrated that early in infection neutrophils infiltration begins 1-week post infection (wpi) and 
peaked at 2-3 wpi in I/St mice infected with an high dose of H37Rv (155). Neutrophils are recruited 
throughout the acute and chronic stages of Mtb infection through the expression of CXCL-1 and 
CXCL-5 by IL-17-RA induction by non-hematopoietic cells (164). Neutrophils isolated from Mtb 
susceptible mice have higher migratory capabilities, survive longer and contain more intracellular 
mycobacteria (155). This suggests that neutrophils may provide a niche for Mtb to grow and hide 
from host immune response. Mtb susceptible (I/St mouse strain) and resistant (A/Sn mouse strain) 
neutrophil motility in response to Mtb cellular components or infected cells was found to be 
increased in Mtb susceptible mouse strains (155). Mtb infected resistant neutrophils were shown 
to be resistant to apoptosis (CD95+/Fas+) and have an impaired life span. In addition to motility, 
susceptible neutrophils (I/St) were able to phagocytose increased amounts of Mtb compared to 
resistant neutrophils (A/Sn) indicating that neutrophil host immunity can impact susceptibility 
 14 
(155). With increased neutrophil infiltration in the lung and lifespan, it has been suggested that 
neutrophils promote infection through the “Trojan Horse” model. The “Trojan Horse” model 
speculates that since neutrophils are able to take up Mtb, hide from the immune system and allow 
for its growth. Mtb induces death responses in neutrophils and when infected, neutrophils become 
apoptotic (annexin v+) and unable to kill Mtb (161, 165). Mtb has a unique set of genes (e.g. ESAT-
6 and CFP-10) encoded in the RD1 (region of deletion 1) that is important for Mtb virulence and 
pathogenesis (165-170). Inhibition of neutrophil apoptosis and limiting of Mtb growth has been 
demonstrated to be RD1-dependent (165, 167). This finding demonstrates that neutrophils are able 
to limit Mtb growth within specific contexts or deficiencies in Mtb.  Data discussed here also 
suggests that impaired neutrophil infiltration, motility, life span and resistance to apoptosis is 
beneficial for combating against susceptibility (155). Thus, it is important that neutrophil 
recruitment and elimination is balanced during infection and disease.  
Studies have demonstrated that NETs are also present in active pulmonary tuberculosis patients 
compared to healthy controls (171, 172).  In human neutrophils that are incubated with Mtb, the 
morphology of the neutrophil is changed – inducing aggregation and the release of fibrous material 
and granules (171). NETs are comprised of cellular DNA, histones and neutrophil granule proteins 
(70). Ramos-Kichik et al. demonstrated that NETs are capable to trapping Mtb but not able to kill 
Mtb (171). NETs immobilizing Mtb in an extracellular environment where neutrophils are also 
able to produce nitric oxide as well as its byproducts, hypochlorous acid and chloramines may aid 
in mediating Mtb control (70).  
Although there have been many studies to determine whether neutrophils are able to kill Mtb, in 
vitro studies have not consistently concluded whether or not neutrophils are able to control Mtb 
growth. In the Mycobacterium marinum (Mm) zebrafish model, neutrophils have been shown to 
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aid in decreasing bacterial burden and control infection (21). When Mtb infected mice transiently 
depleted neutrophils and monocytes via administration of RB6-8C5 antibody, bacterial burdens 
were significantly decreased (20). This finding was also see in Mtb infected rats (173). These 
finding suggests that neutrophil depletion during early infection promotes Mtb growth. Individuals 
who have chronic granulomatous disease (CGD), a disorder where neutrophils are impaired, are 
susceptible to TB (174, 175). Even though there are studies that demonstrate neutrophils contribute 
to Mtb control, there are other studies that demonstrate the opposite. Berry et al. demonstrated that 
ATB individuals an enhanced IFN-inducible gene profile mediate by neutrophils (43). In many 
Mtb mouse studies increased neutrophil accumulation has been positively correlated with Mtb 
burden (155, 176). By identifying host and microbe factors that aid in neutrophils killing of Mtb 
researchers would be able to design treatments to target and enhance the neutrophil’s efficiency in 
killing Mtb.  
1.5.4 Neutrophils and granulomas 
Granulomas consist of myeloid and lymphoid cells that aggregate together to limit dissemination  
(177). Although this response functions to limit mycobacterium growth and dissemination, 
excessive lung damage also occurs. Neutrophil recruitment is not only associated with 
pathogenesis, but also TB granulomas (93, 172, 178, 179). The structure of the granuloma allows 
for immune cells to be in physical contact or influenced by chemokines and cytokines in order to 
mediate this defense. Having IFN-γ, IL-2, IL-12 and TNF-α localized within a granuloma 
promotes Mtb control within a confined area. TNF-α and IFN-γ are important in granuloma 
formation, maintenance and the induction of chemokine production (e.g.  CXCL9, CXCL10 and 
CXCL11) (46, 180, 181). Granulomas formation does not occur visibly until immune responses 
are activated which in mice is typically three weeks from initial infection (182). Granulomas that 
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are protective and within resistant mice are classified as well organized; whereas, Mtb infected 
macrophages are surrounded by activated T cells, mainly Th1 and Th17 cells, which have become 
activated through dendritic cell priming (13, 183). Granulomas with ectopic lymphoid structures 
have been associated with protection and latently infected individuals (184). These structures can 
be described as a T cell encompassed Mtb infected macrophage center (184). In addition to ectopic 
lymphoid structures being associated with disease, decreased amounts of neutrophils and 
S100A8/A9 has also been described as protective characteristics of granulomas (93). In contrast, 
susceptible mice have loosely organized granulomas with random and sparsely distributed 
macrophages throughout the granuloma (183, 185, 186). These granulomas that lack structural 
organization and ectopic lymphoid structures are also associated with susceptibility, disease 
progression and transmission (184, 187). Granulomas during active disease typically have 
increased amounts of bacteria in them compared to latent granulomas (188). Lesions that have 
increased fibrous and calcified environment are associated with bacterial control; whereas, caseous 
granulomas are associated with active disease (188, 189). Necrotic granulomas are associated with 
higher bacterial burdens (13). Th1 responses have been demonstrated to drive granuloma necrosis 
(13). Foamy macrophages are typically a component of these types of granulomas and have 
defective phagocytosis, antigen presentation processing, have increased production of TGF-β, an 
immune suppressive cytokine and have been associated with disease progression (190, 191).  
1.5.5 Chemokines and cytokines  
Neutrophils are able to produce a wide array of chemokines and cytokines – ones that both are 
able to act on neutrophils in an autocrine manner as well as able to act on other immune cells (e.g. 
dendritic cells and macrophages) (70, 192, 193). G-CSF, IL-1β and TNF-α are cytokines made by 
neutrophils that have been shown to be important for neutrophil migration, degranulation and the 
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response of the neutrophil to infection (70, 129, 194-196). After Mtb is recognized by neutrophil 
cell surface receptors (e.g. TLR4), proinflammatory cytokine production (e.g. IL-1β) is induced 
(130, 197). IL-1β has been shown to increase phagocytosis and the anti-microbial activity of 
neutrophils and macrophages (198). Mtb infected mice lacking IL- receptor 1 (IL-1R1) were 
unable to control lung bacterial burden and had a significantly increased mortality rate (199). This 
limited Mtb control correlated with an increase in Mtb infected cells and inflammation, which 
included neutrophils (199). This suggests that IL-1 cytokine production and signaling could play 
an important role in Mtb infection. Additionally, Berry et al. showed that ATB individuals have 
an enhanced type I interferon gene profile that is driven by neutrophils (43). This finding provides 
evidence that neutrophil-dependent gene regulation and production may mediate TB disease.   
In addition to pro-inflammatory cytokines, anti-inflammatory cytokines, specifically TGF-β, have 
also been shown to play a role in TB disease. Stimulated neutrophils have been shown to produce 
TGF-β (200)TGF-β has been associated with TB based on lung samples of individuals with ATB 
(201, 202). In the Aung et al study, data was shown that TGF-β was expressed in over half of 
patients that died within late stage ATB (201). Several studies have shown TGF-β protein levels 
are increased in TB patients, associated with TB reactivation and were decreased during anti-TB 
treatment (203).  
1.5.6 Neutrophil proteins 
Despite the evidence that suggests that neutrophil granules and proteins can kill Mtb and may be 
beneficial during Mtb infection, the presence of neutrophils and their proteins have also been 
shown to contribute to pathology during Mtb infection and disease. Studies have shown that 
exacerbated neutrophil accumulation is not protective and this finding may extend to neutrophilic 
proteins such as S100A8/A9 (176, 204-206). Neutrophils have a wide variety of bactericidal 
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proteins and peptides that are released into the infection environment (70). Human and mouse 
studies have explored the contribution of granule associated neutrophilic proteins to killing Mtb 
(70). Cathepsin G (CG), neutrophil elastase (NE), proteinase 3 (PR3), defensins, cathelicidin (LL-
37), lactoferrin and lysozyme are amongst the proteins that have been interrogated (70, 207). 
Neutrophilic proteins, such as neutrophil human protein 1 (NHP-1), have been shown to directly 
and indirectly contribute to a decrease in bacterial burden. When NHP-1, a neutrophilic protein 
generated in humans, was given to mice intravenously infected with a high dose of H37Rv, lung 
bacterial burden decreased (208).  Activated macrophages that phagocytose neutrophilic granules 
have been indirectly shown to be effective in killing Mtb (96). Interestingly, chronic 
granulomatous disease (CGD) neutrophils incubated with Mtb and demonstrated the ability to limit 
Mtb growth compared to normal neutrophils (174, 175). In general, the presence of neutrophilic 
proteins has been associated with protection and Mtb control. Lower neutrophil counts and protein 
levels of lipocalin-2 was associated with the Black African population and a higher susceptibility 
rate (6). When CG deficient mice (CGKO) were infected during the acute phase of infection, they 
had significantly higher amounts of bacteria in the lungs, but not the spleen or lymph nodes (LN) 
(207). This suggests that CG is important in controlling bacteria in the lungs during the acute stage. 
However when CG and NE are both deficient, lung bacterial burden is even higher than the CGKO, 
indicating that NE has an additive effect in controlling mycobacterial growth (207). The CG/NE 
double knockouts also have increased granuloma size and TNF-α protein levels compared to 
wildtype and CGKO infected mice (207). CG was demonstrated to have mycobactericidal effects, 
in both aerobic and anaerobic conditions, because bacterial burden was significantly decreased in 
cultures with CG (207). The Steinwede et al. have demonstrated that CG and NE proteins were 
beneficial in limiting Mtb growth when given in liposomes (207). Also, lower plasma protein 
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levels of human neutrophil protein 1, 2 and 3 is shown to correlate with an increase in MDR-TB 
(209). These findings suggest that neutrophils that are deficient in specific neutrophilic proteins 
are still able to control Mtb (174).  
S100A8 (MRP8) and S100A9 (MRP14) are constitutively expressed in neutrophils in high 
amounts and can be often found as a heterodimer (S100A8/A9), which is known as calprotectin 
(93, 210, 211). Individually and as a heterodimer, these proteins have been shown to be TLR4 and 
receptor for advanced glycation end products (RAGE) ligands (212, 213). S100A8 and S100A9 
have been shown to be important for neutrophil chemotaxis and have antimicrobial capabilities 
(214). S100A9 is able to increase neutrophil recruitment and CXCL-10, a neutrophil chemokine, 
in the lung (214). S100A9 and S100A8/A9 promote neutrophil recruitment to the lung of naïve 
mice (214). Deletion of S100A8 is embryonically lethal (215). S100A9 deficient mice are 
considered normal, but have lower amounts of S100A8 and are less responsive to chemoattractants 
(216, 217). When adenoviral S100A9 was given to TLR4 deficient mice, lung inflammation and 
pathology increased to wild-type levels (213). Gopal et. al.  showed that S100A8/A9 proteins are 
associated with neutrophil accumulation and inflammation in human, NHP and mouse models 
(93). This finding is interesting and needs to be explored because other neutrophilic proteins are 
known to be protective, but S100A8/A9 enhances TB susceptibility (218-220). S100A8/A9 has 
been shown to be associated with increased susceptibility the role that S100A8/A9 in TB disease 
and infection has not been elucidated. This is a major focus of this thesis.  
1.5.7 TB diagnostics and biomarkers 
Currently, diagnosis of ATB is determined by a sputum culture, X-ray or Computed 
Tomography (CT) scan, TST and clinical signs (53). The gold standard for determining whether 
an individual is infected with Mtb is a sputum test, but takes approximately 3-4 weeks for 
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confirmation occurs (53). Although an estimated 54 million people have been diagnosed and 
treated for TB, there are still unidentified individuals that are infected that have not been 
identified (2). Studying neutrophilic proteins, specifically S100A8/A9, presents a unique 
opportunity to assess whether it would be a diagnostic biomarker for TB. It has been suggested 
that underdiagnosed individuals is due to lack of healthcare or lack of diagnosis (2). To aid this 
problem, the identification of optimal biomarker(s) would need to have a high specificity and 
sensitivity for determining individuals that are healthy, latently and actively infected and be 
available at a low cost.  The identification of biomarker resulting to an earlier diagnosis of an 
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2.1 Abstract 
Neutrophil accumulation is associated with lung pathology during active tuberculosis (ATB). 
However, the molecular mechanism(s) by which neutrophils accumulate in the lung and contribute 
to TB immunopathology is not fully delineated. Using the well-established mouse model of TB, 
our new data provides evidence that the alarmin S100a8/a9 mediates neutrophil accumulation 
during progression to chronic TB. Depletion of neutrophils or S100a8/a9 deficiency resulted in 
improved Mycobacterium tuberculosis (Mtb) control during chronic but not acute TB. 
Mechanistically, we demonstrate that following Mtb infection, S100a8/a9 expression is required 
for upregulation of the integrin molecule CD11b specifically on neutrophils, mediating their 
accumulation during chronic TB disease. These findings are further substantiated by increased 
expression of S100A8 and S100A9 mRNA in whole blood in human TB progressors when 
compared to non-progressors. Importantly, we demonstrate that S100A8/A9 serum levels along 
with chemokines are useful as biomarkers to distinguish between ATB and asymptomatic Mtb-
infected latent individuals. Thus, our results support targeting S100A8/A9 pathways as host-
directed therapy for TB. 
2.2 Introduction 
Mycobacterium tuberculosis (Mtb), the causative agent of the disease tuberculosis (TB), is 
estimated to infect one fourth of the world's population and results in ~1.6 million deaths each year 
(2). In addition, the emergence of multi-drug and extensively drug resistant Mtb strains and 
variable efficacy of the currently used vaccine, Mycobacterium bovis BCG, are barriers to global 
control of TB. Thus, more research is needed to fully understand the mechanisms of TB 
immunopathogenesis that can be targeted to improve host control of Mtb infection.  
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Neutrophil accumulation has been associated with TB disease in humans and mouse models of TB 
(176, 221). Neutrophils are the primary Mtb-infected cell population in the sputum, 
bronchoalveolar lavage (BAL), and cavities of Mtb infected patients (222). In mouse models, 
neutrophils are amongst the first cells infected with Mtb, and are capable of recognizing and 
responding to Mtb infection and displaying effector functions (142, 151). Calprotectin, also known 
as S100A8/A9, is mainly expressed by myeloid cells, specifically neutrophils and monocytes, and 
is a feature of chronic inflammatory diseases such as autoimmune diseases and TB (93, 210, 211). 
S100A8 and S100A9 covalently form the hetero-complex protein S100A8/A9, and bind to 
receptors such as Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products 
(RAGE), which mediates a pro-inflammatory response through nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
signaling (223, 224). We recently demonstrated that S100A8/A9-expressing neutrophils 
accumulated within TB granulomas in human and animal models of TB, and that S100A8/A9 
serum levels coincided with increased neutrophil numbers and enhanced TB disease in active TB 
(ATB) patients (93). However, we did not fully understand the mechanism(s) by which 
S100A8/A9 mediates neutrophil accumulation that may promote TB disease severity. In the 
current study, we demonstrate that S100a8/a9 expression mediated accumulation of lung 
neutrophils in chronically Mtb-infected mice. Additionally, the observed accumulation is mirrored 
by increased S100A8 and S100A9 mRNA in whole blood transcriptional profiles of latently 
infected individuals (LTBI) who progress to ATB disease (progressors), when compared with 
individuals who do not progress to TB disease (non-progressors). These studies suggest that in 
animal models and human progressors, S100a8/a9 expression levels increase during TB 
progression or chronic TB disease. Consistent with a detrimental role for S100A8/A9, mice 
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depleted of neutrophils or deficient in S100a9 exhibit decreased Mtb burden in the lungs during 
chronic infection and TB reactivation. The improved Mtb control in S100a9KO mice coincided 
with reduced lung neutrophil accumulation within TB granulomas, and decreased expression of 
the integrin CD11b on neutrophils. Our mechanistic in vitro studies show that S100a9KO 
neutrophils have defective Mtb uptake, as well as reduced ability to upregulate CD11b integrin 
expression. Importantly, we demonstrate that S100A8/A9 serum levels along with chemokines are 
useful as biomarkers to distinguish between ATB patients and LTBI individuals. Our results 
suggest that targeting S100A8/A9 as host directed therapy in TB would provide novel pathways 
that can be used as adjunct therapy to improve Mtb control.  
2.3 Results  
Depletion of neutrophils during chronic but not acute TB improves Mtb control 
A neutrophil associated transcriptional signature was reported in ATB patients and neutrophil 
accumulation was associated with TB disease in mouse models (93, 176, 221). Consistent with 
this, neutrophils accumulated in the blood during ATB but not in asymptomatic latency in 
macaques infected with Mtb (Figure 2.1A). However, it is unclear if neutrophils play distinct roles 
during the acute and chronic stages of Mtb infection. Thus, we studied the kinetics of neutrophil 
accumulation in the well-established mouse model of low dose aerosol Mtb infection in C57BL/6J 
(B6) mice. Neutrophils accumulated in the lung following infection with Mtb HN878 early, 
starting at 30 days post infection (dpi). Accumulation further increased during chronic stages of 
infection, starting around 60 dpi and continuing until 300 dpi (Figure 2.1B). As we observed 
increased neutrophil accumulation during both acute and chronic stages, we next addressed the 
functional role for neutrophils at the two distinct phases of Mtb infection. We found that treatment 
with 1A8 antibody, which specifically depletes neutrophils (225), during acute Mtb infection did 
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not impact overall lung and spleen Mtb burden (Figure 2.1C). Treatment with 1A8 depleted lung 
neutrophils significantly, but also coincided with increased monocyte and macrophage populations 
and increased production of the chemokine, granulocyte-colony stimulating factor (G-CSF) 
(Figure 2.1D and Supplemental Figure 2.1A). However, despite changes in myeloid cell 
accumulation, the total inflammatory area measured in the lung was not significantly altered 
(Figure 1E). In contrast, 1A8 treatment during chronic Mtb infection led to decreased Mtb burden, 
in both the lung and spleen (Figure 2.1F). Neutrophil depletion during chronic TB did not impact 
other myeloid populations (Supplemental Figure 2.1B), but there was decreased production of 
pro-inflammatory cytokines, such as interleukin (IL)-6 and TNF-α (Figure 2.1G). The area of lung 
cellular inflammation was still not impacted in mice when neutrophils were depleted during 
chronic infection (Figure 2.1H). These data together suggest that despite early accumulation of 
neutrophils, neutrophils do not significantly impact Mtb control during acute stages of infection. 
In contrast, neutrophil accumulation during chronic Mtb infection may have a functional role in 
promoting higher Mtb burden and contributing to increased susceptibility.  
S100a8/a9 is induced during progression to TB disease in animal models and in humans 
S100A8/A9 makes up 40% of the cytoplasmic protein of a neutrophil (226). In addition, we have 
shown that increased serum S100A8/A9 levels correlate with increased neutrophils in peripheral 
blood of ATB patients (93). Accordingly, we found that accumulation of S100a8/a9 levels in Mtb-
infected mouse lungs also closely followed the accumulation of neutrophil influx in the infected 
lung. Early increased production of S100a8/a9 was detected between 15-30 dpi and sustained 
production during chronic infection was observed after 30 dpi (Figure 2.2A). As TB disease 
progressed, S100a8/a9 levels increased, coinciding with the increased accumulation of neutrophils 
observed in chronically Mtb-infected lungs (Figure 2.1B and 2.2A). Thus, we next addressed if 
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S100A8/A9 could be tested as a biomarker for TB disease progression in humans with LTBI. 
Therefore, we analyzed the whole blood transcriptional mRNA levels of S100A8 and S100A9 in 
participants enrolled in the Adolescent Cohort Study (ACS) of TB progressors and matched Mtb-
infected controls (227). Transcript levels of both S100A8 and S100A9 mRNA significantly 
increased in the TB progressors about six months prior to TB diagnosis compared to expression 
levels in matched healthy controls (Figure 2.2B). Thus, our results show that both in mice and in 
humans, an increase in S100a8/a9 expression coincides with TB disease progression. 
S100a9 deficiency improves Mtb control during chronic infection by limiting neutrophil 
accumulation   
Our new data here shows that S100a8/a9 levels increase during chronic Mtb infection in mice and 
human TB progressors, and depletion of neutrophils during chronic infection in mice improves 
Mtb control (Figure 2.1 and 2.2). Therefore, we next assessed the long-term outcome of Mtb 
infection in B6 and S100a9KO mice (217) (which lack functional S100a8/a9) during chronic 
stages of infection with Mtb HN878. While lung and spleen Mtb HN878 CFU was comparable at 
50 dpi, we found that during chronic infection from 100 dpi until 300 dpi, Mtb CFU in the lungs 
of S100a9KO mice were significantly lower, when compared to B6 HN878-infected mice (Figure 
2.3, A and B). This improved Mtb control was also observed during infection with another clinical 
strain, HN563, but not when the lab-adapted Mtb strain H37Rv was used (Supplemental Figure 
2.2, A and B). 
S100A8/A9 plays a key role in neutrophil recruitment and accumulation (228-230) and thus the 
absence of S100a8/a9 may promote improved Mtb control by altering cellular accumulation to the 
lung and regulating inflammation. Coinciding with the timing of improved Mtb control in the lungs 
of S100a9KO mice at 100 dpi, we found that neutrophil accumulation was reduced, while other 
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myeloid subsets such as alveolar macrophages (AMs), recruited macrophages (RMs), monocytes 
and dendritic cells (DCs) were not significantly different in lungs of S100a9KO mice, when 
compared with B6 infected mice (Figure 2.3, C and D). However, at the later stage of chronic 
disease, AMs, DCs, monocytes, and neutrophils were all reduced in S100a9KO mice when 
compared with B6 infected lungs (Figure 2.3, C and D). The localization of MPO-expressing 
neutrophils within TB granulomas during chronic infection was also decreased in S100a9KO mice, 
suggesting that S100a8/a9 expression promoted the accumulation of neutrophils in the lung, 
specifically localization within TB granulomas (Figure 2.3E). Presence and maintenance of B cell 
follicles within lung granulomas has been associated with effective Mtb control (184). Consistent 
with improved protection in the lungs of S100a9KO infected mice at chronic stages, lung B cell 
follicle area was significantly enhanced within TB granulomas (Figure 2.3F). However, despite 
altered accumulation of neutrophils within granulomas in S100a9KO mice, overall inflammatory 
area or the specific type of inflammation (myeloid or lymphocytic) in the lungs of S100a9KO Mtb-
infected mice was not significantly different when compared with Mtb-infected B6 mice 
(Supplemental Figure 2.3, A and B).  
S100A8/A9 binds to RAGE (231), and delivery of RAGE inhibitor (FPS-ZM1) to Mtb-infected 
mice during the chronic stages of infection significantly decreased Mtb burden similar to levels 
observed in S100a9KO mice (Figure 2.4A). Although inflammation was not significantly 
decreased in RAGE-treated mice, B cell follicle size was significantly increased within TB 
granulomas (Figure 2.4, B and C). These results together suggest that absence of S100A8/A9 
expression or inhibition of its receptor function both improve Mtb control during chronic TB. To 
further experimentally test the role of S100A8/A9 in TB reactivation and disease progression, we 
used the Cornell mouse model of TB reactivation where mice were infected with Mtb, treated with 
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antibiotics, following which reactivation of Mtb was assessed. Our data show that while B6 mice 
that received antibiotic chemotherapy reactivated significantly elevated Mtb CFU in the lung, 
S100a9KO mice exhibited significantly lower rates of reactivation and harbored lower lung Mtb 
CFU when compared with B6 mice (Figure 2.4D). In conjunction with lower Mtb CFU, while 
inflammation was not altered, neutrophil accumulation was significantly decreased in lung 
granulomas of S100a9KO mice (Figure 2.4, E and F). These results suggest that while 
S100A8/A9 expression coincides with neutrophil accumulation and improved Mtb control, 
S100A8/A9 expression did not directly regulate inflammation during TB. 
S100a8/a9 expression regulates CD11b expression on neutrophils during chronic 
tuberculosis 
As neutrophil accumulation was significantly decreased in S100a9KO Mtb-infected mice, we next 
determined whether surface expression of the integrin CD11b, a key molecule in leukocyte 
adhesion and migration (232), was differentially expressed in myeloid cells in S100a9KO Mtb-
infected mice when compared with B6 Mtb-infected mice. We observed that CD11b surface 
expression was significantly decreased within lung neutrophils in S100a9KO Mtb-infected mice 
during chronic stages of infection, whereas lung monocytes and RMs had no significant changes 
in CD11b expression (Figure 2.5A). Gr-1 (Ly6G/Ly6C) surface expression was also assessed, but 
no significant changes were seen in any lung myeloid cell population during both acute and chronic 
stages of infection in S100a9KO mice when compared with B6 Mtb-infected mice (data not 
shown). As myeloid cells such as neutrophils and monocytes are among the primary producers of 
S100A8/A9 (211, 233), we addressed if adoptive transfer of CD11b+ cells producing S100A8/A9 
can reverse the improved Mtb control seen in S100a9KO Mtb-infected mice. Accordingly, CD11b+ 
cells transferred into S100a9KO mice resulted in increased lung Mtb burden, suggesting that a 
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CD11b myeloid population was contributing to the increased susceptibility during Mtb infection 
(Figure 2.5B). These data were corroborated by decreased lung protein levels of neutrophil 
attracting chemokines CXCL-1 and MIP-2 in S100a9KO mice during chronic infection (Figure 
2.5C). Taken together, absence of S100A8/A9 during chronic Mtb infection reduces neutrophil 
localization, decreased expression of CD11b expression on neutrophils, and adoptive transfer of 
CD11b cells reversed the protection observed in S100a9KO Mtb-infected lung.  
S100A8/A9 regulates CD11b expression on neutrophils during Mtb infection  
Our data points to a critical role for S100a8/a9 in regulating CD11b expression specifically on 
neutrophils to modulate accumulation into the lung. To mechanistically address the role of 
S100a8/a9 in regulation of CD11b expression on neutrophils and Mtb control, bone marrow 
derived neutrophils were infected with reporter-expressing Mtb, and bacterial uptake and 
neutrophil marker expression was assessed. While B6 neutrophils were more readily infected with 
Mtb, S100a9KO neutrophils exhibited less ability to take up Mtb (Figure 2.6A). Furthermore, 
CD11b expression was significantly upregulated on B6 Mtbhi neutrophils but not as highly induced 
in S100a9KO Mtbhi neutrophils (Figure 2.6B). Indeed, S100a9KO neutrophils also expressed 
lower levels of CD11b even in uninfected controls, as published before  (217), suggesting that 
while S100a8/a9 regulates the expression of CD11b at homeostatic levels, this effect is much more 
profound upon Mtb infection. Similar results were obtained when Gr-1 and CD18 levels were 
measured on S100a9KO Mtb-infected neutrophils, when compared with B6 Mtb-infected 
neutrophils (Figure 2.6B). To address if live Mtb infection was required for CD11b upregulation, 
we then tested if stimulation with heat killed (HK) Mtb, or components of Mtb will similarly 
regulate the S100a8/a9-dependent effects on CD11b regulation. We found that HK Mtb and 
stimulation with culture filtrate protein (CFP) and cell wall components (CW) of Mtb similarly 
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induced an S100a9-dependent CD11b upregulation on neutrophils, suggesting that live Mtb 
infection was not necessary (Figure 2.6C). Since S100a8/a9 is known to induce NF-κB signaling, 
we also wanted to understand the role of NF-κB signaling in mediating CD11b upregulation. We 
isolated neutrophils from IKKfl/fl LysMCre mice, which lack canonical IKK and NF-κB signaling 
in LysM-expressing cells. We found that lack of NF-κB signaling reduced Mtb infection in 
neutrophils (Figure 2.6D), and NF-κB signaling was required for upregulation of CD11b and 
Gr-1 on Mtb-infected neutrophils (Figure 2.6E). These results together demonstrate that 
absence of S100a8/a9 expression in neutrophils significantly impacts Mtb uptake and CD11b 
induction following Mtb infection, in part dependent on NF-κB signaling. These results together 
provide novel insights into the molecular mechanisms that mediate CD11b upregulation in a 
S100a8/a9 dependent manner.  
S100A8/A9 can function as a biomarker of TB disease progression 
Our data demonstrate that S100A8/A9 mRNA levels increased during progression to TB in 
humans. Thus, we wanted to next address if serum S100A8/9 levels can be used as biomarkers to 
distinguish ATB patients from healthy LTBI and uninfected healthy controls (HC). S100A8/A9 
serum protein levels were significantly higher in ATB patients compared to HCs (Table 2.1, 
Figure 2.7A). Importantly, we also found significantly increased S100A8/A9 serum levels in 
LTBI Tuberculin Skin Test (TST+) and Quantiferon+ (QFT+) house hold contacts of ATB patients, 
and LTBI TST+ QFT+ individuals with occupational exposure to TB, when compared with 
uninfected HCs (Figure 2.7A). S100A8/A9 levels were also higher in LTBI TST+QFT+ 
individuals with occupational exposure to TB when compared with LTBI TST+ QFT- individuals 
with similar occupational exposure to TB (Figure 2.7A). These results suggest that S100A8/A9 
levels could serve as an easily measurable biomarker of TB disease progression in LTB 
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individuals. Additionally, we assessed if increased S100A8/A9 serum protein was only increased 
during ATB or was also increased in other acute and chronic inflammatory pulmonary diseases. 
While S100A8/9 serum protein levels were not higher in patients with Chronic Obstructive 
Pulmonary Disease (COPD), S100A8/A9 serum levels were high in influenza infected patients 
(Figure 2.7A). These results suggest that S100A8/A9 serum measurements may be used as 
biomarkers for TB, while taking into consideration clinical symptoms which may confound the 
measurements.  
As CXCL-1 and CXCL-10 serum levels were additionally increased in ATB patients (Table 2.1), 
we next sought to understand whether combining S100A8/A9 with CXCL-1 and CXCL-10 serum 
protein levels will improve biomarker performance for distinguishing ATB from LTB than 
S100A8/A9 alone (93). Median serum biomarker concentrations, with interquartile ranges, across 
the three groups of participants is included in Table 2. The medians were the lowest in the 
uninfected HCs for all biomarkers, followed by levels in LTB individuals, and the highest 
expression was noted in the ATB group. Overall and pairwise comparisons were listed in Table 3, 
where the differences in the distribution of the biomarkers across all levels were significant when 
comparisons were made between ATB and LTB, as well as ATB and HC. For a threshold of 114 
pg/ml, CXCL-1 could differentiate between ATB and HC groups with a sensitivity of 88.4% (95% 
CI, 0.78-0.96) and a specificity of 61.5% (95% CI, 0.42-0.80); while for CXCL-10, a threshold of 
302 pg/ml would differentiate between ATB and HC with a sensitivity of 86.5% (95%CI, 0.76-
0.94) and a specificity of 57.7% (95% CI, 0.38-0.76). For S100A8/9, a threshold of 1805 pg/ml 
would differentiate between ATB and HC with a sensitivity of 92.3% (95% Cl, 0.84-0.98) and a 
specificity of 76.9% (95% Cl, 0.57-0.92). Notably, S100A8/A9 levels were the only significant 
determination when LTB and HCs were compared pairwise and not when CXCL-1 and CXL-10 
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were determined for pairwise comparisons between the LTB vs HC (Table 2.2). Furthermore, 
receiver operating characteristic (ROC) analysis was applied to appraise the diagnostic values of 
the 3 biomarkers individually and their combination (Table 2.3 and 2.4). Combining S100A8/A9 
along with CXCL-1 and CXCL-10 into a biomarker signature improved differentiation between 
ATB and HCs (0.9467, 95% Cl, 0.88-1.0) when compared with utilizing CXCL10 and S100A8/A9 
as combined biomarker signatures (0.9268, 95% Cl, 0.85-0.99, Table 2.3 and 2.4. Figure 2.7B). 
These results together suggest that use of S100A8/A9 in combination with other chemokines 
should be further pursued for use as a biomarker for TB disease and TB disease progression. 
2.4 Discussion   
Neutrophils have recently been implicated as drivers of immunopathogenesis of TB in human and 
animal models (93, 221, 234). However, the molecular mechanisms by which neutrophils regulate 
TB immunopathogenesis are not clearly understood. In this study, we demonstrate that neutrophils 
accumulate during progression to TB disease in Mtb-infected humans and mice, and play a 
detrimental role during chronic TB disease in mice. Additionally, S100a8/a9 levels mirror the 
neutrophil accumulation in the lung in mice, and S100a9 deficiency in mice results in improved 
Mtb control during chronic disease. We show that the mechanism by which S100A8/A9 
contributes to increased TB disease pathogenesis is by regulating the expression of the integrin 
CD11b, which is required for neutrophil accumulation in the lung (217, 229). Furthermore, 
S100A9 deficiency also reduces TB reactivation in mice, and use of RAGE inhibition results in 
improved Mtb control. Finally, our human studies suggest that S100A8/A9 levels along with 
expression of chemokines such as CXCL-1 and CXCL-10 may serve as biomarkers to identify 
LTBI and ATB from HCs. Together, our results demonstrate that S100A8/A9 play pivotal 
 34 
functions in regulating neutrophil accumulation during TB, primarily through their effects on 
CD11b expression, thus providing novel insights into the immunopathogenesis of TB.  
Although neutrophil accumulation has been associated with increased disease in mouse and NHP 
models, as well as human TB, it is still unclear whether neutrophils have protective or pathological 
functions in Mtb infection (5, 96, 155, 164, 221). Despite neutrophils being one of the first cell 
types infected with Mtb (142), our results show that neutrophil depletion during acute Mtb 
infection has no significant impact on Mtb control or TB pathology. These results provide formal 
evidence that neutrophils do not play a protective role during acute Mtb infection. In contrast, our 
data showing that depletion of neutrophils during chronic Mtb infection improves Mtb control 
clearly establishes a detrimental role for neutrophils during the chronic stages of Mtb infection. 
Interestingly, while both neutrophil depletion and S100A8/A9 deficiency improved Mtb control, 
overall inflammatory lung disease was not impacted. In the case of neutrophil deficiency, it is 
possible that transient depletion of neutrophils was not sufficient to impact overall inflammation 
and prolonged neutrophil depletion may be required to impact lung pathology. During S100A8/A9 
deficiency, while overall inflammatory disease was trending towards decreased inflammation, 
these data were not significant. However, the reduced accumulation of neutrophils into TB 
granulomas coincided with increased formation of B cell containing granulomas, which our studies 
have previously shown to be associated with improved Mtb control (184). Together, our results 
demonstrate that neutrophils and S100A8/A9 may play key roles in modulating TB 
immunopathogenesis by driving neutrophil accumulation. 
A mechanism by which S100A8/A9 regulates TB pathogenesis is likely by directly regulating 
CD11b expression on neutrophils. While S100a9 deficiency did not impact CD11b expression on 
neutrophils during the early stages of Mtb infection, deficient mice express lower CD11b levels 
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on neutrophils during chronic TB. In contrast, in S100a9KO bone marrow neutrophils, CD11b 
expression is significantly lower in uninfected controls, and upon Mtb infection, upregulate CD11b 
to a lesser extent than B6 bone marrow neutrophils. Considering these baseline differences in 
CD11b expression in bone marrow neutrophils, it is intriguing why differences in CD11b 
expression do not occur in S100a9KO mice until day 100 following Mtb infection. The nature of 
the microenvironment (e.g. presence of other pro-inflammatory chemokines, prolonged Mtb 
infection and stimulation, etc.) may contribute to differences observed in in vitro studies and ex 
vivo isolated neutrophils. Additionally, it is of considerable interest that while S100a9KO mice are 
protected from infection with a clinical Mtb isolate, HN878, S100a9KO mice do not show any 
protection when infected with a lab adapted Mtb strain, H37Rv. Thus, our data suggest that 
S100a8/a9 may play homeostatic roles in regulating CD11b expression in bone marrow 
neutrophils, which following infection and induction of inflammatory cytokine signals, these 
effects may be amplified. Neutrophil chemotaxis has been associated with cytoskeletal 
reorganization and actin polymerization and regulation. S100a9 deficient neutrophils had actin 
defects when responding to IL-8 stimulation, suggesting that S100a9 has a role in cytoskeletal 
dynamics and reorganization (217). Functional actin coordinates cell surface integrin regulation 
(e.g. CD11b/CD18), which could impact neutrophil migration and adhesion. Together, this 
suggests that S100a8/a9 expression in the lung may induce chemokines that mediate neutrophil 
accumulation, potentially directly act as a chemoattractant for neutrophils (229), but also by 
regulating the expression of CD11b to regulate additional neutrophil migration into the lung.  
S100A8/A9 is known to interact with TLR4 and RAGE, while CD11b expression can be driven 
by interactions with TLR4 on neutrophils (212, 235). Thus, S100A8/A9 may engage TLR4 and 
RAGE to upregulate CD11b expression on neutrophils. Adoptive transfer of CD11b cells increased 
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susceptibility in S100a9KO mice, suggesting that CD11b immune populations, namely neutrophils 
or monocytes expressing S100a8/a9, are the likely cellular population mediating increased 
susceptibility during chronic TB. The utilization of RAGE inhibitor, FPS-ZM1, is protective in 
animal models of emphysema and Alzheimer's disease (224, 236). During chronic TB, we show 
that transient use of RAGE inhibitors is protective and is sufficient to decrease lung Mtb burden, 
but not lung inflammation. Whether use of RAGE inhibitor limits neutrophil accumulation and 
thus reduces the Mtb niche is not fully explored and should be the focus of future studies. 
Excitingly, our data showing that S100a8/a9 deficiency delays TB reactivation suggests that 
RAGE inhibitors may be potentially used as host directed therapeutics in combination with current 
antibiotic regimens to improve Mtb control and should be further studied.  
The rapid diagnostic test for detection of TB recommended by the World Health Organization is 
an automated PCR assay that detects mycobacteria in sputum expectorated by patients (WHO). 
However, access remains restricted in low resource settings, and sputum-based microscopy to 
identify Mtb still remains the most commonly used diagnostic for TB, but this method is primarily 
capable of identifying ATB patients. Therefore, new non-sputum based screening tools for 
identifying individuals with ATB are required so that they can be prioritized for clinical 
investigation and treatment. Blood biomarkers that can differentiate progression of LTB to 
subclinical disease and ATB, failure of TB treatment and TB relapse would provide additional 
tools to improve TB diagnosis and combat the global TB epidemic. Several studies have explored 
the use of host transcriptional biosignatures as diagnostic biomarkers for progression of TB and to 
predict risk of human TB disease (221, 237). Although these studies propose the use of 
transcriptional gene signatures as screening or triage tests for TB, the costs and technology 
associated with RT-PCR or RNA sequencing may still limit use of these biomarkers as diagnostic 
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in low resource setting. Our published studies have shown that ATB patients in India, Mexico and 
South Africa all reliably exhibit increased expression of serum S100A8/9 proteins when compared 
with HC (93), and now in QFT+LTBI individuals. Serum is more amenable to developing a simple 
screening test that may be easier to translate into a point of care format (e.g. the Quantum Blue 
assay, which works also for sputum and urine). Additionally, our new studies also show that 
S100A8/A9 along with chemokine such as CXCL-1 and CXCL-10 serum protein levels reliably 
able to differentiate between ATB and HC, and although less effective but still significantly can 
discriminate between ATB and QFT+ LTBI. Furthermore, that S100A8/A9 is not significantly 
increased during other chronic pulmonary diseases such as COPD cohort suggests that S100A8/A9 
may be useful as a biomarker for a triage test to rule out individuals who do not have TB, such that 
biomarker+ individuals then get followed up for further TB diagnosis. Thus, further validation of 
the use of S100A8/A9, CXCL-1, and CXCL-10 in different geographical cohorts and in treatment 
failure and relapse studies will be useful and timely.  
In summary, our studies have mechanistically described a pivotal role for S100A8/A9 proteins in 
mediating TB pathogenesis through regulation of CD11b and neutrophil recruitment. Additionally, 
our experimental studies targeting the S100A8/A9 signaling pathway project a novel pathway for 
host directed therapeutics for TB. A more mechanistic understanding of the role of S100A8/A9 
proteins further validates the development of S100A8/A9 and related biomarkers as novel 
diagnostics for TB.  
2.5 Methods 
Mice and NHP Mtb infection 
C57BL/6 (B6) mice were purchased from Jackson Laboratory (Bar Harbor, ME).  S100a9KO was 
obtained from Dr. Thomas Vogl (217)and mice were bred within the Washington University in St. 
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Louis animal facility. Both sexes between the ages of 6-8 weeks were used. All mice were 
maintained and used in accordance with the approved Institutional Animal Care and Use 
Committee (IACUC) guidelines at Washington University in St. Louis. Mtb strains were cultured 
and mice were aerosol infected with ~100 colony forming units (CFU), as described previously 
(184). At specific time points post infection, lungs were harvested, homogenized, and serial 
dilutions of tissue homogenates plated on 7H11 agar plates to determine Mtb CFU. For reactivation 
experiments, mice were treated with rifabutin (Sigma) (100 mg/L) and isoniazid (Sigma) (200 
mg/L) for 6 weeks and mouse tissue was then harvested at 140 dpi. For rhesus macaques infected 
with Mtb, we used clinical data stored in the Animal Records System (ARS) at the Tulane National 
Primate Research Center. Macaques were chosen if they were experimentally infected with Mtb 
(either CDC1551, Erdman or H37Rv strains) during 2007-2015 and exhibited either ATB or were 
latently infected. Post-infection, data were obtained weekly from animals until euthanasia or 
necropsy. Neutrophil percentages in the blood were obtained from complete blood counts 
performed at the same time as serum chemistry. 
Adoptive transfer of CD11b+ cells  
Lung cell suspensions were prepared from the lungs of B6 mice 100 dpi following HN878 
infection. CD11b+ cells were enriched from the lung suspension using magnetic selection with 
CD11b microbeads (Miltenyi Biotec, Auburn, CA) per manufacturer’s instructions. 50 µl (1x106 
cells) of this suspension (72.4% purity) was administered intratracheally to HN878-infected mice 
at 100 dpi. These mice were harvested on 120 dpi as indicated. 
RAGE-inhibitor treatment 
 39 
RAGE signaling was inhibited starting 205 dpi as previously described (224) through daily 
intraperitoneal (i.p.) injection of 1 mg/kg RAGE-specific blocker FPS-ZM1 (Tocris) or DMSO 
(control). Mice were euthanized 15 days after treatment. 
Neutrophil Depletion 
Neutrophils were depleted as described (143) using 300 µg anti-mouse Ly6G (BioXcell) or isotype 
IgG (Sigma). Briefly, forin acute infections (less than 21 dpi), mice were given 300 µg of anti-
mouse Ly6G every other day between 10-20 dpi intra-peritoneally (i.p). In chronic infections, mice 
were given 300 µg of anti-mouse Ly6G every other day between 95-105 dpi via intraperitoneal 
(i.p.) injections. 
Lung Cell Preparation and Flow Cytometry  
Lung cell suspensions were prepared, stained, collected and analyzed for flow cytometry as 
described before (184). Fluorochrome-labeled antibodies specific for CD11b (M1/70, BD), CD11c 
(HL3, BD), Gr-1 (RB6-8C5, eBioscience) were used in this study. Cells were collected using a 
FACSJazz with FACS Sortware software. Cell populations were gated based on their forward by 
side scatter characteristics and the frequency of specific cell types was analyzed using FlowJo 
version 7.6.5 (Tree Star Inc, CA). Lung alveolar macrophages were gated as CD11c+ CD11b-, lung 
myeloid dendritic cells were gated on CD11c+ CD11b+, neutrophils as CD11b+ Gr-1hi, recruited 
macrophages were annotated as CD11b+ Gr-1lo, and monocytes were gated on CD11b+ Gr1int cells 
as in Dunlap et al 2018 (22). 
In vitro neutrophil infections 
Neutrophils were isolated from the bone marrow using the mouse neutrophil isolation kit (Miltenyi 
Biotec, Auburn, CA). Neutrophils were infected at an MOI of 1 for three hours. Neutrophil uptake 
was derived from neutrophil infection with Mtb HN878-mCherry. CD11b MFI was also assessed 
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in neutrophils treated with heat-killed Mtb HN878 (1x106 CFU) or Mtb HN878 culture filtrate 
protein and cell wall extracts (10 µg/ml). Fluorochrome-labeled antibodies specific for CD11b 
(M1/70, BD), CD18 (M18/2, Biolegend), Gr-1 (RB6-8C5, eBiosciences), were used in this study.  
Lung histology 
Lungs from Mtb-infected mice were perfused with 10% neutral buffered formalin and were 
paraffin embedded. Lung sections were stained with hematoxylin and eosin (H&E) and processed 
for light microscopy. Images were obtained using Zeiss Axioplan 2 microscope and were recorded 
with a Zeiss AxioCam digital camera. Sections were probed with rabbit anti-MPO (PB9057, 
BosterBio; dilution 1:100) and biotinylated rat anti-mouse Ly6G (clone IA8, Biolegend; dilution 
1:100) to detect neutrophils or with anti-B220 (clone RA3-6B2, BD Pharmingen; dilution: 
1/100) to detect B cells. Primary antibodies were detected with Cy3 donkey anti-rabbit Ig G(711-
166-152, Jackson ImmunoResearch Laboratories; dilution 1:200) and Alexa Fluor 488 streptavidin 
(A21208, Thermo Fisher Scientific; dilution 1:200). B cell follicles were assessed through the 
automated tool of the Zeiss Axioplan 2 microscope (Zeiss, Thornwood, NY, USA), and total 
area and average size was calculated in squared microns. Myeloid and lymphocyte areas were 
acquired with stained slide images using a Hamamatsu Nanozoomer 2.0 HT system with NDP 
scan image acquisition software and was quantified using Visiomorph image processing 
software (Visiopharm, Broomfield, CO).  
RNA sequencing data from Adolescent Cohort Study progressors and controls 
We compared gene-level mRNA expression levels of S100A8 and S100A9 in Mtb-infected 
adolescents enrolled into the Adolescent Cohort Study (ACS) who remained healthy during 2 years 
of study follow-up (controls) (n=106) or who progressed to microbiologically confirmed, active 
TB (progressors) (n=44), as described (227, 237). Adolescents who were Mtb+ at enrollment, or 
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developed ATB disease more than 6 months after Mtb infection was first detected were included 
in our analyses. Each progressor had two healthy matched controls based on age, gender, ethnicity, 
school of attendance, and presence or absence of prior episodes of tuberculosis disease. 
Participants were excluded if they were ATB+ within 6 months of enrollment or QFT and/or TST 
conversion, or if they were HIV infected. Study protocols were approved by The Human Research 
Ethics Committee of the Faculty of Health Sciences, University of Cape Town. Written informed 
consent was procured from parents/legal guardians as well as from every adolescent. Participants 
with diagnosed or suspected tuberculosis disease were referred to a study-independent public 
health physician for treatment according to national tuberculosis control programs of the country 
involved. RNA was extracted from PAX gene tubes and RNA-sequencing performed as described 
(227, 237). Prospective RNA-Seq data of progressors were realigned to the time point at which 
active TB was diagnosed. Differences in gene-level mRNA expression between each progressor 
sample and the average of demographically matched control samples were computed using the 
published ACS metadata (227, 237). Time To Diagnosis values were assigned to each sample 
according to the original definitions. The log2 fold change values between progressor and control 
biomarkers were modeled as a nonlinear function of Time To Diagnosis for the entire population 
using the smooth-spline function in R with three degrees of freedom. Ninety-nine percent 
confidence intervals for the temporal trends were computed by performing 2000 iterations of spline 
fitting after bootstrap resampling from the full dataset.  
ATB cohort 
We recruited patients (n = 52) with confirmed ATB. The diagnosis of ATB was made by the 
conventional microscopic detection of acid-alcohol resistant bacteria as well as culture of Mtb in 
Lowenstein-Jensen medium in serial, non-concentrated sputum samples, radiological studies, 
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physical examination and clinical history. All patients with ATB were residents of the urban and 
metropolitan areas of Mexico City and some patients were residents from different states of the 
south and central area of Mexico including Veracruz, Oaxaca, Puebla and Chiapas. Patients with 
ATB, excluding patients with HIV and cancer, were recruited at the INER Tuberculosis Clinic in 
a period between 2015 and 2017. 
At the same time, household contacts of ATB patients who are TST+QFT+ LTBI (n = 36) were 
recruited in the first two months of diagnosis. The criteria for inclusion of contacts of ATB patients 
were: 1) Subjects of legal age (18 to 54) willing to sign the letter of consent; 2) Subjects in close 
contact with the index case of ATB and 3) Subjects willing to provide the blood samples needed 
to participate in the study. In addition, a group of individuals (n = 28) belonging to health personnel 
(resident physicians of the pulmonology specialty) and administrative medical staff of the INER, 
considered as an occupational risk population of which both TST+QFT+ (n=19) and TST+QFT- 
(n=9) were included. Also, a group of uninfected healthy individuals (TST-QFT-) were also 
recruited (n=26). Only patients with ATB, LTBI, and healthy controls who agreed to participate 
in the study and who signed an informed consent letter were included. The study was reviewed 
and approved by the Institutional Research Committee with protocol number B04-15. After the 
consent signature, 20 ml of blood anticoagulated with EDTA and 10 ml of blood without 
anticoagulant was used to isolate serum for the purpose of performing the experimental analysis. 
G-CSF, IL-6, TNF-α, MIP-2, S100A8/A9, CXCL-1 and CXCL-10 protein quantification 
Levels of G-CSF, IL-6 and TNF-α, CXCL-1 and MIP-2 in mouse lung homogenates were 
measured using a mouse Luminex assay (Linco/Millipore). Circulating levels of S100A8/A9 were 
measured in serum samples by ELISA using the DuoSet ELISA Development kit for human 
S100A8/S100A9 heterodimer (Cat: DY8226, R&D Systems Inc., Minneapolis, MN, USA), 
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according to the manufacturer’s instructions. Serum samples were diluted 1:4000 in regent diluent 
(1% BSA in PBS). Absorbance was read at 450 nm and 540 nm (for wavelength correction) using 
the Synergy HT microplate ELISA reader (BioTek Inc., Winooski, VT, USA). Serum levels of 
CXCL-1 were measured by CXCL1 Quantikine ELISA Kit (Cat: DGR00B, R&D Systems Inc.)  
according to the manufacturer’s instructions. For this assay, samples were diluted 1:2. Absorbance 
was read at 450nm and 540nm using the Synergy HT microplate ELISA reader (BioTek Inc.). 
Serum levels of CXCL-10 were assessed by Luminex using the Bio-Plex Pro CXCL10 Set (Bio-
Rad Laboratories, Inc., Hercules, CA, USA) according to the manufacturer’s instructions. The 
samples were read in a BioPlex-200 instrument. The results were analyzed using the BioPlex 
software V 4.1 (Bio-Rad Laboratories). 
Statistics 
Differences between the means of two groups were analyzed using the two tailed Student’s t-test in 
GraphPad Prism 5 (La Jolla, CA). Multiple groups were analyzed using 1-way ANOVA and Tukey’s 
post-test analysis. Differences are noted as significant when a p-value is less than or equal to 0.05 (*), 
less than or equal to 0.01 (**), less than or equal to 0.001 (***), and less than 0.0001 (****).  
The distribution of the biomarkers in human samples was examined and expressed as a median and 
interquartile range (IQR). The differences in the distributions across the groups was evaluated using the 
Kruskal-Wallis nonparametric test where the Dwass, Steel, Critchlow-Fligner Method was used to check 
for Pairwise Two-Sided Multiple Comparison Analysis (238-240). The diagnostic efficiency of the 
individual biomarkers and their combinations was assessed by receiver operating curve (ROC) analysis 
where the AUC and associated 95% confidence intervals (CIs) were determined. A nonparametric 
approach was used to compare the correlated receiver operating characteristic (ROC) curves without 
adjustments for pairwise comparisons (241). Logistic regression analysis was performed to determine 
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the predictive probability of these biomarkers on the each of the outcome combinations. The level of 
significance was set to 0.05 and all analysis were 2-sided. Statistical analyses and figures were 
performed with SAS 9.4 (SAS Institute Inc., Cary, NC, USA). 
Study Approval 
For human studies, written informed consent from participants was received under a protocol approved 
by the Ethics Committee of the Instituto Nacional de Enfermedades Respiratorias (Mexico City) and the 
the Human Research Ethics Committee of the Faculty of Health Sciences (Cape Town). Protocols 
involving the use of animals were approved by IACUC at Washington University in St. Louis and Tulane 
National Primate Research Center. All of the experiments were performed in accordance with the 
protocols. 
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2.7 Figure Legends 
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Figure 2.1. Neutrophil depletion during chronic TB improves Mtb control. (A) The number of blood 
neutrophils from Rhesus macaques with ATB (n=8) or LTBI (n=10) were measured at dpi following 
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Mtb infection or at necropsy (N). B6 mice were aerosol-infected with ∼100 CFU Mtb HN878. (B) 
neutrophil accumulation was determined by flow cytometry at 0,3,5,14,20,30,60,100,150,300 dpi. B6 
mice were infected with Mtb HN878 and administered IgG (n = 5-10) or 1A8 (n = 5-10, 300 µg/dose) 
i.p. every other day. (C) Bacterial burden in the lung and spleen was determined by plating on 21 dpi. 
(D) Lung homogenates were analyzed for G-CSF protein expression by ELISA on 21 dpi. (E) Pulmonary 
inflammation was quantified on formalin-fixed paraffin embedded (FFPE) lung sections from 21 dpi 
samples stained with H&E. B6 mice were infected with HN878 and administered IgG (n = 4-5) or 1A8 
(n = 4-5, 300 µg/dose) i.p. every other day. (F) Bacterial burden in the lung and spleen was determined 
by plating on 106 dpi. (G) Lung homogenates were analyzed to measure levels of IL-6 and TNF-α 
proteins at 106 dpi using Luminex assays. (H) Pulmonary inflammation was quantified on FFPE lung 
sections from 106 dpi tissues stained with H&E. (A-G) Student’s t-test between isotype and 1A8 treated 
mice. The data points represent the mean (±SEM) of values. P ≤ 0.05 (*), P ≤ 0.01 (**),P ≤  0.001 (***), 




Figure 2.2. S100A8/A9 mRNA levels are indicators of TB disease progression in mice and 
humans with TB. B6 mice (n=3-5) were aerosol-infected with ∼100 CFU Mtb HN878. (A) Lung 
S100A8/A9 levels were determined by ELISA at 0, 5,8,12,15,30,50,100,150,300 dpi. (B) Kinetics 
of S100A8 and S100A9 mRNA expression over time, expressed as log2 fold change between bin-
 49 
matched progressors (n=44) and controls (n=106) and modeled as non-linear splines (dotted lines). 
Light green shading represents 99% CI and dark green shading 95% CI for the temporal trends, 
computed by performing 2000 spline fitting iterations after bootstrap resampling from the full 
dataset. The deviation time (day), calculated as the time point at which the 99% CI deviates from 
a log2 fold change of 0, is indicated by the vertical red line. P ≤ 0.05 (*) and P ˂ 0.0001 (****). 
 50 
 
Figure 2.3. S100a8/a9 deficiency protects mice during chronic TB. B6 (n=5-10) and S100a9KO 
(n=5-9) mice were aerosol-infected with ∼100 CFU Mtb HN878. (A, B) Lung and spleen bacterial 
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burden was determined by plating at different 50,100,150,300 dpi. Lung myeloid population cell 
counts were enumerated in B6 and S100a9KO HN878-infected mice using flow cytometry at 
50,100,150,300 dpi and (C) neutrophils and other (D) other myeloid cells are shown. FFPE lung 
sections were used to carry out immunofluorescence staining for Ly6G (green), MPO (red), and 
DAPI (blue) or B220 (green), CD3 (red) and DAPI (blue). (F) Total area occupied by B cell 
follicles was determined using the morphometric tool of the Zeiss Axioplan microscope. AMs 
alveolar macrophages, DCs dendritic cells, RMs recruited macrophages. (A-B, D-G) Student’s t-
test between B6 and S100a9KO, (C) 1-way ANOVA with Tukey’s post test. The data points 
represent the mean (±SEM) of values from 5-10 mice. P ≤ 0.05 (*), P ≤ 0.01 (**),P ≤  0.001 (***), 
and P ˂ 0.0001 (****). 
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Figure 2.4 Targeting the S100A8/A9 pathway limits susceptibility to chronic TB and TB 
reactivation. Mtb-infected B6 and S100a9KO (n=10) mice were treated with RAGE inhibitor (1 
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mg/kg RAGE-specific blocker FPS-ZM1 (n=5) or DMSO (n=5)) at 205 dpi for 15 days and (A) 
lung bacterial burden at 220 dpi was determined by plating, (B) pulmonary inflammation was 
quantified on FFPE lung sections stained with H&E and (C) area occupied by B cell follicles was 
quantified histologically. B6 (n=9) or S100a9KO (n=13) infected mice were treated with (100 
mg/l) and isoniazid (200 mg/l) for 6 weeks and mice organs were then harvested and homogenized 
at 140 dpi to determine reactivation of Mtb infection. (D) Lung bacterial burden was determined 
by plating, (E) pulmonary inflammation was quantified on FFPE lung sections stained with H&E, 
and (F) quantification of Ly6G (green), MPO (red) neutrophils was carried out in FFPE lung 
sections. (A-F) Student’s t-test. The data points represent the mean (±SEM) of values from 5-13 
mice. P ≤ 0.05 (*), P ≤ 0.01 (**),P ≤  0.001 (***), and P ˂ 0.0001 (****). 
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 Figure 2.5 CD11b+ cells mediate improved protection in S100a9KO Mtb-infected mice. B6 
(n=5-24) and S100a9KO (n=5-24) mice were aerosol-infected with ∼100 CFU Mtb HN878. (A) 
CD11b mean fluorescence intensity (MFI) on neutrophils, monocytes and RMs was determined 
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using flow cytometry at 50, 100, 150 and 300 dpi. S100a9KO (n=6) infected mice received 
CD11b+ purified cells from B6 mice (50 µl containing 1x106 cells) intratracheally at 100 dpi. (B) 
Lung bacterial burden was determined by plating at 120 dpi. (C) Lung homogenates were analyzed 
by Luminex for KC/CXCL-1 and MIP-2 at 300dpi. (A and C) Student’s t-test between B6 and 
S100A9KO per timepoint, (C) 1-way ANOVA with Tukey’s post test. The data points represent 
the mean (±SEM) of values from 5-24 mice. P ≤ 0.05 (*), P ≤  0.001 (***), and P ˂ 0.0001 (****). 
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Figure 2.6 S100A8/9 regulates CD11b expression on neutrophils. Bone marrow neutrophils 
were isolated and infected with mCherry labeled HN878 (MOI of 1) for 3 hours. (A) Mtb uptake 
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by neutrophils was determined in B6 (n=5) and S100a9KO (n=5) neutrophils using flow 
cytometry. (B) MFI of CD11b, Gr-1 and CD18 expression on uninfected (UI) and highly infected 
(Mtbhi) neutrophils was determined by flow cytometry. Neutrophils from B6 mice were left 
untreated (UI) or treated with heat killed Mtb (HK), Mtb culture filtrate protein (CFP) and Mtb cell 
wall preparations (CW) (C) MFI of CD11b expression on uninfected or treated neutrophils for 3 
hours and CD11b MFI was determined by flow cytometry. Bone marrow neutrophils from IKKfl/fl 
LysMCre mice and IKKfl/fl mice were ,infected with Mtb (MOI 1) and (E) Mtb uptake, (F) CD11b 
and Gr-1 MFI was assessed using flow cytometry. (A-F) Student’s t-test. The data points represent 
the mean (±SEM) of values from 5 biological replicates. P ≤ 0.05 (*), P ≤ 0.01 (**),P ≤  0.001 
(***), and P ˂ 0.0001 (****). 
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Fig 2.7 S100A8/A9 proteins can be used as a surrogate biomarker to distinguish between 
ATB and healthy controls. Heathy uninfected controls (TST-QFT-) (n=26), LTBI household 
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contacts (TST+QFT+LTBI) (n=36), LTBI occupational exposed individuals who are TST+QFT+ 
(n=19), LTBI occupational risk individuals who are TST+QFT- (n=9), ATB (n=52), patients with 
chronic obstructive pulmonary disease (COPD) (n=16), and influenza (Flu) (n=18) patient serum 
were collected and (A) S100A8/A9 levels were determined by ELISA. (B) ROC curves of single 
(top panel) and top 3 biomarker combinations (bottom panel) for ATB vs HC (left panel) and ATB 
















Supplemental Figure 2.1 Neutrophil depletion in chronic Mtb infection does not alter 
accumulation of other myeloid cell populations in the lung. B6 mice were infected with HN878 
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and administered IgG (n = 10) or 1A8 (n = 9-10, 300 µg/dose) i.p. at 10, 12,14,16,18 and 20 dpi. 
(A) Lung myeloid cell populations were enumerated in isotype and 1A8 treated mice using flow 
cytometry at 21 dpi. B6 mice were were infected with HN878 and administered IgG (n = 4-5) or 
1A8 (n = 4-5, 300 µg/dose) i.p. at 95, 97, 99, 101, 103 and 105 dpi. (B) Lung myeloid cell 
populations were enumerated in isotype and 1A8 treated mice using flow cytometry at 106 dpi. 
AMs alveolar macrophages, DCs dendritic cells, RMs recruited macrophages. The data points 
represent the mean (±SEM) of values. Student’s t-test between isotype and 1A8 treated mice. P ≤ 
0.05 (*), P ≤ 0.01 (**),P ≤  0.001 (***), and P ˂ 0.0001 (****). 
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Supplemental Figure 2.2 S100A8/A9 deficiency does not impact susceptibility with lab-
adapted Mtb H37Rv infection. B6 (n=4-5) and S100a9KO (n=5) mice were aerosol-infected with 
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∼100 CFU of drug resistant W-Beijing strain HN563. (A) Lung and spleen bacterial burden was 
determined by plating at 50 and 100 dpi. B6 (n=4-5) and S100a9KO (n=5) mice were aerosol-
infected with ∼100 CFU Euro-American lab-adapted strain H37Rv. (B) Lung and spleen bacterial 
burden was determined by plating at 50 and 100 dpi. The data points represent the mean (±SEM) 
of values from 4-5 mice. Include statistical information. P ≤ 0.05 (*), P ≤ 0.01 (**),P ≤  0.001 





Supplemental Figure 2.3 Lack of S100A9 during chronic TB does not impact overall lung 
inflammation.   
B6 (n=5-7) and S100a9KO (n=5-8) mice were aerosol-infected with ∼100 CFU HN878. (A) 
Pulmonary inflammation was assessed and quantitated on H&E stained FFPE lung sections from 
B6 and S100a9KO mice. (B) Lymphoid or myeloid inflammation quantification of FFPE lung 
section in B6 and S100a9K mice. (A-B) Student’s t-test between B6 and S100A9KO. The data 
points represent the mean (±SEM) of values from 5-8 mice. P ≤ 0.05 (*), P ≤ 0.01 (**),P ≤  0.001 
(***), and P ˂ 0.0001 (****). 
Table 2.1 Descriptive Statistics (Median and Interquartile Range) of biomarkers in Active 
TB, Latent TB and Healthy controls  
  Active TB Latent TB Healthy C 
  Median IQRa 
Media
n  IQRa 
Media
n IQRa 
CXCL1 145.92 122.23, 184.57 129.66 100.1, 158.01 106.84 98.12, 134.61 
CXCL10 
1140.8











aInterquartile Range (IQR) 
 
Table 2.2 Differences in the distribution across the three individual biomarkers 
  
Pvaluea 
P value for Pairwise comparisonsb 
Active TB vs Latent 
TB 
Active TB vs 
Healthy C 
Latent TB vs Healthy 
C 
CXCL1 0.0001 0.0198 <.0001 0.1539 
CXCL10 <.0001  <.0001  <.0001 0.997 
S100A8/A9 <.0001 <.0001 <.0001 0.0206 
aKruskal Wallis Test 
bDwass, Steel, Critchlow-Fligner Method  
 








Active TB vs Health Controls       
S100A8/A9 0.9083 0.8373 0.9793 
CXCL1 0.8003 0.6930 0.9076 
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CXCL10 0.8536 0.7685 0.9386 
S100A8/A9+CXCL1+CXCL10a 0.9467 0.8893 1.0000 
CXCL10+ S100A8/A9a 0.9268 0.8633 0.9903 
CXCL10+CXCL1 0.9157 0.8448 0.9866 
CXCL1+ S100A8/A9a 0.9231 0.8537 0.9925 
Active TB vs Latent TB       
S100A8/A9 0.8575 0.7897 0.9254 
CXCL1 0.6421 0.5454 0.7387 
CXCL10 0.8665 0.797 0.9359 
S100A8/A9+CXCL1+CXCL10a 0.8968 0.8398 0.9538 
CXCL10+ S100A8/A9a 0.8925 0.8326 0.9524 
CXCL10+CXCL1a 0.8841 0.8201 0.9480 
CXCL1+ S100A8/A9 0.8581 0.7905 0.9256 
Latent TB vs Health Controls       
S100A8/A9a 0.6777 0.5434 0.8120 
CXCL1 0.6230 0.5082 0.7378 
CXCL10 0.5049 0.3610 0.6488 
S100A8/A9+CXCL1+CXCL10a 0.6701 0.5507 0.7895 
CXCL10+ S100A8/A9a 0.6593 0.5227 0.7958 
CXCL10+CXCL1 0.6148 0.4994 0.7303 
aBolded are the top 3 model combinations in terms of the AUC  
 
 
Table 2.4 Comparison of the models top 3 AUCs within each group using the ROC macro 
(reference: http://support.sas.com/kb/25/addl/fusion_25017_6_roc.sas.txt) 
Models 
pvalue for pairwise and overall c statistic 
comparisons 







Overall p value 0.1040 
Active TB vs Latent TB   
S100A8/A9+CXCL1+CXCL10 vs 
CXCL1+ S100A8/A9 0.3419 
S100A8/A9+CXCL1+CXCL10 vs 
CXCL10+ S100A8/A9 0.3937 
S100A8/A9+CXCL1 vs 
S100A8/A9+CXCL10 0.7048 
Overall p value 0.3937 
Latent TB vs Health Controls   
 67 
S100A8/A9+CXCL1+CXCL10 vs 
CXCL10+ S100A8/A9 0.8355 
S100A8/A9+CXCL1+CXCL10 vs 
S100A8/A9 0.8824 
S100A8/A9+CXCL10 vs S100A8/A9 0.1628 
Overall p value 0.3768 
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3.1 Introduction 
Mycobacterium tuberculosis (Mtb),  the causative bacterial pathogen of the disease tuberculosis 
(TB) causes approximately 1.6 million deaths each year and infects approximately one fourth of 
the world's population (2). In addition, multi-drug and extensively drug resistant Mtb strains have 
become prevalent, making TB extremely difficult to treat. Currently, BCG vaccine which is 
derived from Mycobacterium bovis BCG is available as a preventable vaccine against Mtb 
infection; however its efficacy is variable. It is imperative to understand Mtb infection, TB disease 
and elucidate host protective mechanisms in order to improve host defenses against TB. 
Understanding such immune mechanisms will also enrich the discovery and implementation of 
host directed therapies against TB.   
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Transforming growth factor (TGF)-β comes in three isoforms and has been demonstrated to 
contribute to several biological process, including immune regulation and inflammatory responses 
(242). TGF-β is necessary for lung organogenesis and hemostasis and is associated with various 
respiratory diseases, such as pulmonary fibrosis and emphysema (243, 244). TGF-β exerts its 
activity by being activated and binding to TGFβR- I or II cell surface receptors initiating the Smad 
signaling pathway, resulting in the transcription of transcription factors, coactivators and 
corepressors (245, 246). 
Increased serum levels of TGF-β and expression in TB lesions in lung samples of individuals with 
active TB disease (ATB) have been shown (201, 202). In the Aung et al study, TGF-β expression 
was shown to be located close to alveolar walls and not in the granuloma (201). Aung et al. 
observed TGF-β was expressed in over half of patients that died within late stage ATB (201). 
Additionally, Bonecini-Almeida showed TGFβRI and TGFβRII expression was increased in TB 
patients compared to patients with other lung diseases and healthy volunteers (202).  When 
stimulated with Mtb antigens, monocytes from TB patients produce increased levels of TGF-β 
(203). Several studies also show that TGF-β serum levels are increased in TB patients, are 
associated with TB reactivation and decrease during treatment (203). TGF-β is a known promoter 
of T regulatory cells and a suppressor of inflammation (247-249). Since increased TGF-β levels 
are associated with TB disease, limiting TGF-β signaling should have a beneficial effect on the 
host. One such therapeutic could be CWHM 12, a TGF-β inhibitor. CWHM 12 is a small molecule 
inhibitor of αv integrins. Integrins, especially αv, are important mediators of pulmonary fibrosis. 
Signaling through the TGF-β receptors requires matured TGF-β isoforms. Lack of integrins, such 
as αv, has been shown to mimic deficiencies of mice that lack TGF-β1 and TGF-β3 (250). 
Henderson et al. demonstrated that αv is a mediator of organ fibrosis, specifically pulmonary 
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fibrosis (251). Mice treated with CWHM 12 during bleomycin induced pulmonary fibrosis were 
significantly decreased. Since lung fibrosis can be a characteristic of TB (252), we sought to 
determine if CWHM 12 treatment inhibits pulmonary fibrosis and enhances Mtb control during 
infection. 
In this study, we assessed the effect of CWHM 12 on the host responses during Mtb infection. We 
used the C3Heb/FeJ (FeJ) Mtb infection model because it is able to recapitulate necrotic and 
hypoxic granulomas, which are a characteristic of human TB (253, 254). We observed that CWHM 
12 treatment in FeJ infected mice decreased bacterial burden during early infection. The most 
effective treatment resulted in a 1 log bacterial burden decrease. This decrease in bacterial burden 
also resulted in decreased accumulation of alveolar macrophages and neutrophils and increased 
recruited macrophages. Enhanced protection resulted from decreased iNOS production, increased 
collagen in the whole lung and granulomas as well as significant decreases in MIP-2 and IL-10 
production. This study provides evidence that inhibition of TGF-β and using CWHM 12 may be a 
host directed therapy to TB disease.   
3.2 Results 
TGFβ inhibitor targeting αv integrin improves Mtb control in mice 
FeJ mice have been shown to be increasingly susceptible to Mtb starting at 15 dpi, where lung 
bacterial burden is significantly increased compared to parental mouse strains, C3H and B6, and 
necrotic lesions are observed (Kramnik 1998). These necrotic lesions, mainly composed of 
macrophages, neutrophils and lymphocytes, very similar to what is seen in humans (Irwin 2015, 
Smith 2016) Previously, CWHM 12 was shown to decrease bleomycin induced pulmonary 
fibrosis; however, the effect of CWHM 12 in Mtb pulmonary infection is unknown. Using 
treatment timepoints 0-14 dpi (start of infection), 14-28 dpi (progression from acute to chronic) 
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and 30-44 dpi 9chroinc TB disease) would allow us to assess at which stage of Mtb infection would 
CHWM 12 be effective in controlling bacterial burden and fibrosis. We delivered CWHM 12 or 
our vehicle control to HN878 Mtb infected FeJ mice at three different stages of Mtb infection. 
Treatment with CWHM 12 delivered the start of infection resulted in a significant decrease in lung 
bacterial burden compared to the control group (Fig. 3.1A). Lung and spleen bacterial burden 
control was further increased when treatment was delivered after the establishment of infection 
and the innate immune response (14-30 dpi) (Fig 3.1B).  Upon CWHM 12 treatment in the later 
stages (30-44 dpi) after the establishment of infection, there was no differences in lung Mtb 
bacterial control (Fig. 3.1C). These data suggest that CWHM 12 treatment is most effective during 
the acute stages of infection.  
CWHM 12 treatment mediates improved Mtb control by decreasing myeloid cell 
recruitment.  
CWHM 12 treatment is effective against Mtb growth when delivered up to 30 dpi; however, we 
also wanted to assess whether this improved Mtb control was associated with cellular recruitment 
and changes in lung inflammation. Even though mice treated at the start of infection did had similar 
levels of inflammation, when treatment was given after the establishment of infection 
inflammation increased Fig. 3.2A). However, when CWHM 12 treatment was given at during 
chronic infection, inflammation was significantly increased (Fig. 3.2A). Although, significant 
inflammation did not occur due to CWHM 12 treatment during acute stages of Mtb infection, 
changes in cellular recruitment was observed. To determine which cellular population(s) were 
modulated during CWHM 12 treatment of Mtb infected FeJ mice, we measured the accumulation 
of lung alveolar macrophage, dendritic cell, neutrophil, monocyte and recruited macrophages. 
When CWHM 12 treatment increased Mtb control correlated with a significant decrease in alveolar 
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macrophage and neutrophil populations; whereas, recruited macrophages were increased in the 
lung (Fig. 3.2B). Total lung cellular accumulation between the groups showed that a significant 
increase in cellular influx in the CWHM 12 treated group when compared to controls, which 
further supports the increased inflammation observed in the lungs of these mice (Fig. 3.2A). 
CWHM 12 suppresses iNOS and cytokine production, but enhances collagen in lung  
Since we saw significant lung macrophage accumulation, we determine whether CWHM 12 
treatment influence macrophage activation through iNOS production. To determine this, we 
stained for iNOS and observed that the CWHM 12 treated group had significantly less iNOS+ cells 
(Fig. 3.3A). Since we saw significant changes in macrophages and iNOS production it may suggest 
macrophages within the treated lungs are polarizing toward a M1 state.  
Previously, Henderson et al. demonstrated that CWHM 12 reduces bleomycin induced pulmonary 
fibrosis; however, it is unknown how CWHM 12 impacts Mtb induced pulmonary fibrosis. Fibrosis 
was significantly increased in the lungs and granulomas of CWHM 12 treated mice (Fig. 3.3B-C). 
These data demonstrate that CWHM 12 treament enhances pulmonary fibrosis in the Mtb mouse 
model. 
To further understand and elucidate why recruitment of alveolar macrophages, neutrophil and 
recruited macrophages increased in response to treatment, we assessed cytokine production in the 
lung. We observed IL-10 and macrophage Inflammatory Protein 2 (MIP-2) were significantly 
decreased in the treatment group (Figure 3.3D). MIP-2 is a chemoattractant for neutrophils, so its 
decreased production in the lungs may result in a decrease in neutrophil pulmonary localization 
(255-257). Altogether, these data suggest CWHM 12 induces decreased pulmonary bacterial 
burden by modulating alveolar, neutrophil and recruited macrophages recruitment and suppressing 
iNOS, MIP-2 and IL-10 production. 
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3.3 Discussion 
TGF-β is able to modulate innate and adaptive immune responses, as well as fibrosis. Active 
TGF-β is able to signal through TGF-β receptors 1 and 2 and signals Smad proteins to 
translocate to the nucleus and act as transcription factors for target genes.  It has been shown 
through several studies that Active Tuberculosis is associated with increased production of TGF-
β. Mtb infected mice had enhanced lung protection when IL-10 deficient (258, 259).  A 
therapeutic that inhibits or suppresses TGF-β may aid in enhancing host immune protection and 
Mtb control. Throughout this study, we sought to establish whether CWHM 12 treatment during 
Mtb infection mediates a protective host immune response and controls Mtb. We have 
demonstrated that CWHM 12 treatment given early in infection aids in Mtb control, treatment is 
most effective after infection has been established. Inhibition of TGF-β at different stages of Mtb 
infection resulted in varying degrees of Mtb control, if CWHM 12 were to be used as a host 
directed therapeutic the time in which to administer it would need to be taken into consideration.    
CWHM 12 treatment, improved Mtb control and this was associated with decreased alveolar 
macrophages and neutrophils and increased recruited macrophages. Decreased numbers of 
alveolar macrophages and neutrophils may enhance the protective response because both 
populations have been shown to be reservoirs of Mtb (4, 22, 222). MIP-2 is produced by alveolar 
macrophages and is a recruitment chemokine for neutrophils (260, 261). Decreased amounts of 
MIP-2 suggest that reduced cellular presence of alveolar macrophages may lead to the decreased 
production of MIP-2 and recruitment of neutrophils.  
In addition to a decrease in MIP-2 production during treatment, IL-10 protein levels were also 
decreased. IL-10, normally associated with TGF-β, also induces an anti-inflammatory response 
and has also been associated with ATB (202, 258). Mtb infected mice had enhanced lung 
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protection when the mice are IL-10 deficient or IL-10 depleted (258, 262).  Denis and Ghadirian 
have shown that decreased amounts of IL-10 contribute to increased Mycobacterial control in 
macrophages (262). Decreased amounts of alveolar macrophages and neutrophils not only 
present a reduction in niches for Mtb growth, but in the case of alveolar macrophages it also 
serves as an environment of Mtb control due to IL-10 suppression (262). It is promising that in 
conjunction with TGF-β inhibition, IL-10 production is also decreased during CWHM 12 
treatment. In addition to an anti-inflammatory role, TGF-β has been computationally suggested 
to contribute to granuloma formation (263). Macrophages are major components of granulomas, 
so CWHM 12 may also be mediating the formation of a protective granuloma that is able to 
contain and control Mtb. Characteristics of a “protective” granuloma have increased B cell 
follicles, increased iNOS, decreased hypoxia and decreased perivascular cuffing (184, 264). 
Classical M1 stage macrophages typically are also associated with iNOS and proinflammatory 
cytokine production; whereas, M2 polarization is associated with anti-inflammatory cytokine and 
chemokine production.  Although, not specifically quantified this iNOS data paired with 
population changes may indicate that CWHM 12 may drive macrophages to polarize toward a 
M1 state. In order to reaffirm this hypothesis, Mtb presence along with protective granuloma 
characteristics within control treated and CWHM 12 treated granulomas would need to be 
assessed. Additional in vitro experiments are needed to assess whether CWHM 12 has 
mycobactericidal abilities as a sole compound and when in the presences of macrophages. 
Increased TGF-β in active TB patients has been established and suggests that the diminished 
production of TGF-β would be associated with treatment. Mtb infected non-human primates that 
were treated with TB chemotherapy (rifampin and isoniazid) for two months showed that TGF-β 
levels decreased as antibiotic treatment progressed (265). This decrease was shown to be 
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associated with decreased signaling through to SMAD-2/3 (265). Interestingly within this NHP 
study, collagen levels increased similar to what we see in our model. Since we observe the 
greatest decrease in lung bacterial burden after Mtb infection has been established, it would be 
beneficial to assess the efficacy of CWHM 12 treatment in conjunction with standard TB 
treatment.  
Here we have demonstrated that CWHM 12 TGF-β inhibition resulted in controlling Mtb at 
different stages of infection. Along with this enhanced control, iNOS decreased and collagen 
production increased within granulomas. Increased collagen in the lung and granuloma may 
indicate a more fortified granuloma that is able to prevent Mtb dissemination. Overall, this paper 
demonstrates that CWHM 12 treatment enhances Mtb control, mediates pulmonary cellular 
populations, as well as the micro and structural environment of the lung and granuloma.   
3.4 Methods 
Mice 
C3HeB/FeJ (FeJ) mice were purchased from Jackson Laboratory (Bar Harbor, ME) and bred 
within Washington University in St. Louis animal facility. Mice used were 6-8 weeks and also 
sex matched. All mice were maintained and used in accordance with the approved Institutional 
Animal Care and Use Committee (IACUC) guidelines at Washington University in St. Louis.  
Bacterial Strains 
Mtb strain HN878 (BEI Resources) was cultured in Proskauer Beck medium containing 0.05% 
Tween 80 to mid-log phase and frozen in 2 ml aliquots at -80oC. Mice were aerosol infected with 
approximately 100 Mtb colony forming units (CFU). At 30 dpi, organs were harvested, 
homogenized and serial dilutions of tissue homogenates plated on 7H11 agar plates and CFU 
determined. 
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Preparation of lung cell suspensions  
Lung cell suspension was prepared from Mtb infected FeJ lungs as described by Gopal et al 2014 
Next, lungs were perfused with cold saline (with heparin) prior to dissecting them with sterile razor 
blades in chilled DMEM. Dissected lung tissue was then incubated in DMEM containing 
collagenase (0.7 mg/ml; Sigma-Aldrich) and DNase (30 µg/ml; Sigma-Aldrich) at 37oC, 5% CO2 
for 30 min. Digested lung tissue was passed through a 70 µm pore size nylon tissue strainer 
(Falcon; BD Biosciences). Single cell suspension was treated with Gey’s solution to lyse any 
residual red blood cells and washed twice before counting using a Coulter Counter.  
Osmotic pump installation 
For all studies, CWHM 12 and CWHM 96 (vehicle) were both solubilized in 50% DMSO (in 
sterile water) and dosed to 100 mg per kg body weight per day. Drug or vehicle (50% DMSO) was 
delivered by implantable ALZET osmotic minipumps (Durect, Cupertino, CA). Pumps were 
inserted subcutaneously 14 day post infection. Lungs were harvested after 30-45 days post 
infection.   
Lung histology 
Lungs from Mtb-infected mice were perfused with 10% neutral buffered formalin and were 
paraffin embedded. Lung sections were stained with hematoxylin and eosin (H&E) and processed 
for light microscopy. Sections were probed with F4/80, iNOS and DAPI.  Images were obtained 
using Zeiss Axioplan 2 microscope and were recorded with a Zeiss AxioCam digital camera. To 
visualize collagen deposition, Masson’s trichrome staining (Sigma-Aldrich) was performed 
according to the manufacturer’s instructions. Images were obtained using Zeiss Axioplan 2 
microscope and were recorded with a Zeiss AxioCam digital camera. Trichrome images were 
obtained using the Hamamatsu Nanozoomer 2.0 HT system with NDP scan image acquisition 
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software and was quantified using Visiomorph image processing software (Visiopharm, 
Broomfield, CO).  
Flow cytometry 
Lung cell suspensions were prepared, stained, collected and analyzed for flow cytometry as 
described in Khader et al 2011. Fluorochrome-labeled antibodies specific for CD11b (M1/70), 
CD11c (HL3) and Gr-1 (RB6-8C5) were used in this study. Cells were collected using a FACSJazz 
with FACS Diva software. Cell populations were gated based on their forward by side scatter 
characteristics and the frequency of specific cell types was calculated using FlowJo (Tree Star Inc, 
CA). Lung alveolar macrophages were gated as CD11c+ CD11b-, lung myeloid dendritic cells were 
gated on CD11c+ CD11b+, neutrophils as CD11b+ Gr-1hi, recruited macrophages were annotated 
as CD11b+ Gr-1lo, and monocytes were gated on CD11b+ Gr1int cells as in Desvignes et al 2012 
(266). 
Quantitation of protein production  
 
IL-10 and MIP-2 protein levels were measured using a mouse Luminex assay (Linco/Millipore). 
 
Statistical analysis 
Differences between the means of two groups were analysed using the two tailed Student’s t test 



















Figure 3.1 Treatment with CWHM 12 leads to decreased bacterial burden in Mtb HN878 
infected FeJ mice. FeJ mice were aerosol infected with ~100 CFU of Mtb HN878. Bacterial 
burden in the lung and spleen were determined by plating after 30 or 45 days post infection (dpi). 
Lung and spleen bacterial burden from (a) 0-14 dpi, (b) 14-28 dpi, (c) 30-44 dpi mice treated with 
CWHM12. (b) H&E staining and (c) quantification of cellular infiltration of mice harvested 30 
dpi. Original magnification for (a).  Error bars represent means ± SD. *P ≤ 0.05, ** P ≤ 0.005, *** 







Figure 3.2 CWHM 12 increases recruited macrophages within the lung during Mtb HN878 
infection. FeJ mice were aerosol infected with ~100 CFU of Mtb HN878 and the lungs were 
harvested at 30 or 45 dpi. (a) Pulmonary inflammation was assessed and quantitated on H&E 
stained FFPE lung sections from Control and CWHM12 mice. (b) Lung myeloid cell populations 
The total number of (a) cells was determined using a Coulter Counter The percentage of (b) AMs 
alveolar macrophages, DCs dendritic cells, RMs recruited macrophages. Error bars represent 







Figure 3.3 CHWM 12 suppresses iNOS, IL-10 and MIP-2 and increases collagen production 
during Mtb infection. FeJ mice were aerosol infected with ~100 CFU of Mtb HN878 and treated 
with CWHM12  14-28 dpi. FFPE lung sections were used to carry out (a) immunofluorescence 
staining for F4/80 (green), iNOS (red), and DAPI (blue), (b, ) trichrome staining and 
quantifications of whole lung and granulomas. (d) Protein levels of MIP-2 and IL-10 were 
determined by luminex assay. Error bars represent means ± SD. group.  *P ≤ 0.05, ** P ≤ 0.005, 



































Conclusions and Future Directions 
Previous studies have demonstrated that neutrophils respond and are effectors of 
immunopathogenesis of TB in human and animal models (43, 93). Neutrophilic mechanisms that 
contribute to TB immunopathogenesis are not fully elucidated. In this thesis, I demonstrate that 
neutrophil accumulation occurs during TB infection and progression to disease Mtb-infected 
humans and mice. Particularly, I show that neutrophils have a pathogenic role during chronic TB 
disease in mice. Previous data from Gopal et al. demonstrated that S100A8/A9 serum levels 
correlated with neutrophil cell count, but the data presented here further provides mechanistic 
evidence t that S100a8/a9 lung concentrations parallel lung neutrophil accumulation in mice. The 
data presented in this thesis provides evidence that S100A8/A9 mediated TB susceptibility and 
reactivation and is associated with increased neutrophil accumulation to the lung and may be 
dependent on CD11b surface expression on neutrophils. Together, the human data collected 
provides evidence that S100A8/A9 serum levels in combination with CXCL-1 and CXCL-10 are 
able to distinguish ATB patients from HCs. Overall, data presented in this thesis on S100A9 
demonstrates that S100A8/A9 promotes lung neutrophil accumulation during TB that may be 
mediated through CD11b expression on neutrophils, thus providing a new perspective in the role 
neutrophils play in the immunopathogenesis of TB.  
In addition to identifying S100A8/A9 playing a role in chronic TB, this thesis also demonstrates 
that TGF-β plays a role in Mtb infection. Increased levels of TGF-β, a cytokine, in the serum has 
been associated with ATB. The second study within this thesis sought to understand how TGF-β 
was mediating its effect during Mtb infection and determining whether an TGF-β inhibitor is able 
to control infection.  CWHM 12 treatment and transient TGF-β inhibition is able to aids in Mtb 
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control, being most effective after infection has been established. During TGF-β inhibition and 
Mtb control, decreased neutrophil accumulation in the lung was observed. This finding mirrors 
findings from the S100a9 deficient Mtb model, indicating neutrophils indeed have a role in Mtb 
infection.  
Although there are many mouse, NHP, and human studies that have associated  neutrophil 
accumulation to TB progression and disease, it is still unclear whether neutrophils have protective 
or pathological functions in Mtb infection (5, 43, 96, 155, 164). It has been well established that 
neutrophils are considered as one of the first cell types infected with Mtb (142). Neutrophil 
depletion during the acute stage of infection showed no significant change in lung or spleen 
bacterial burden suggesting that neutrophils have no significant impact on Mtb control or TB 
pathology during the acute stage. However, neutrophil depletion during the chronic stage of 
infection significantly decrease lung and spleen bacterial burden suggesting that neutrophils play 
a pathogenic role during this stage. Interestingly, while both neutrophil depletion and S100A8/A9 
deficiency improved Mtb control, overall inflammatory lung disease was not impacted. In the case 
of neutrophil deficiency, it is possible that transient depletion of neutrophils was not sufficient to 
impact overall inflammation and prolonged neutrophil depletion may be required to impact lung 
pathology. The functionality of neutrophils may also change depending on the stage of infection. 
To determine if this is correct, RNAseq from lung neutrophils isolated from Mtb infected mice 
would assess whether neutrophil gene expression is different depending on the stage of infection. 
Data from these isolated neutrophils may illuminate additional neutrophilic factors and 
mechanisms that promote susceptibility or protection during Mtb infection. Since I observed that 
decreased neutrophil accumulation occurred during CWHM 12 treatment, it would be beneficial 
to assess whether the protective neutrophil gene expression profile is conserved during anti-TB 
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treatment. Understanding whether a neutrophil changes its gene expression profile during infection 
and during anti-TB treatment will expound the TB and neutrophil community. 
During S100A8/A9 deficiency in the mouse model, there was an overall trend towards decreased 
inflammation (data not significant) even though neutrophil accumulation was significantly 
decreased. The reduced neutrophil accumulation within the S100a9 deficient mice also coincided 
with decreased amounts of neutrophils present and an increase in B cells in the TB granulomas. 
Previous studies published by our lab have demonstrated that increased B cells in TB granulomas 
were associated with improved Mtb control (184). Additional studies into the connection between 
S100A8/A9 and granuloma formation should be assessed since the data presented here suggests 
that it promotes the formation of granulomas that do not control Mtb. Together, our results 
demonstrate that neutrophils and S100A8/A9 may play key roles in modulating TB 
immunopathogenesis by driving neutrophil accumulation. 
In both S100a9 deficient mice and TGF-β treated mice, neutrophil accumulation was associated 
with a significant decrease in lung bacterial burden. This finding in addition to the neutrophil 
depletion data suggests that neutrophils may provide a niche for harboring Mtb. To further 
understand how S100A8/A9 contributes to Mtb growth, in vitro bactericidal assays should be done 
in the presence and absence of neutrophils to assess whether S100A8/A9 solely promotes Mtb 
growth or if it is neutrophil dependent. The same assays should be applied to TGF-β to determine 
its sole effect on Mtb growth or if it is cell dependent. Elucidating how S100A8/A9 is able to 
promote Mtb growth would be a novel finding because in most bacterial infections, S100A8/A9 is 
actually effective against killing extracellular pathogens (218, 267, 268). Currently, there is not 
much literature detailing how TGF-β limits Mtb growth, so identifying this would also be 
beneficial to the TB field.   
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In this Mtb mouse model, a suggested mechanism by which S100A8/A9 regulates TB pathogenesis 
is through the upregulation CD11b expression on neutrophils. Interestingly, S100a9 deficiency 
impacted CD11b expression only on neutrophils and not monocytes or recruited macrophages in 
the chronic stage of infection. In vitro and in vivo studies slightly mirror each other because both 
S100a9 deficient neutrophils had lower expression of CD11b when infected. It is important to note 
that CD11b expression differences S100a9KO mice did not occur until 100 dpi. The nature of the 
microenvironment (e.g. presence of other pro-inflammatory chemokines, prolonged Mtb infection 
and stimulation, etc.) may contribute to differences observed in in vitro studies and ex vivo isolated 
neutrophils. An adoptive transfer of CD11b cells increased susceptibility in S100a9KO mice, 
suggesting that CD11b cellular populations, specifically neutrophils or monocytes expressing 
S100a8/a9, are the likely cellular population mediating increased susceptibility during chronic TB. 
Using Mtb infected CD11b deficient mice will allow for the assessment of whether CD11b 
promotes Mtb susceptibility. Since this thesis main focus the impact of neutrophils on Mtb 
infection, it would be ideal to have a CD11b floxed mouse under a MPR8 cre promoter, to 
specifically determine how CD11b deficiency in the neutrophil impacts TB infection and disease. 
Additionally, it is of considerable interest that while S100a9KO mice are protected from infection 
with HN878 and HN563 (hypervirulent strains), S100a9KO mice do not show any protection when 
infected with H37Rv (a lab adapted strain). It would be informative to assess how S100a9 
deficiency promotes Mtb control or susceptibility in other Mtb strains. Establishing the impact of 
S100A8/A9 on other Mtb strains, especially clinical or multidrug resistant strains, would be 
clinically relevant.  
The data presented in this thesis demonstrates there is a defect in lung neutrophil accumulation, 
which may be dependent on CD11b integrin surface expression. These data garners the question 
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of whether S100A8/A9 impacts neutrophil migration within our Mtb model. To determine whether 
S100A8/A9 impacts neutrophil migration, transwell experiments with infected neutrophils 
migrating to a neutrophil chemoattractant (e.g. CXCL-1) may be used.  Neutrophil chemotaxis has 
been associated with cytoskeletal reorganization and actin polymerization and regulation. S100a9 
deficient neutrophils had actin defects when responding to IL-8 stimulation, suggesting that 
S100a9 has a role in cytoskeletal dynamics and reorganization (217). Functional actin coordinates 
cell surface integrin regulation (e.g. CD11b/CD18), which could impact neutrophil migration and 
adhesion. Together, this suggests that S100a8/a9 expression in the lung may induce chemokines 
that mediate neutrophil accumulation, potentially directly act as a chemoattractant for neutrophils 
(229), but also by regulating the expression of CD11b to regulate additional neutrophil migration 
into the lung.  
S100A8/A9 is known to interact with TLR4 and RAGE, while CD11b expression can be driven 
by interactions with TLR4 on neutrophils (212, 235). Thus, S100A8/A9 may engage TLR4 and 
RAGE to upregulate CD11b expression on neutrophils. RAGE inhibitor, FPS-ZM1, has been 
shown to be protective emphysema and Alzheimer's disease animal models (224, 236). During 
chronic TB, we show that transient use of RAGE inhibitors is protective and is sufficient to 
decrease lung Mtb burden, but not lung inflammation. Whether use of RAGE inhibitor limits 
neutrophil accumulation and thus reduces the Mtb niche is not fully explored and should be the 
focus of future studies. Excitingly, our data showing that S100a8/a9 deficiency delays TB 
reactivation suggests that RAGE inhibitors may be potentially used as host directed therapeutics 
in combination with current antibiotic regimens to improve Mtb control and should be further 
studied. In addition to the RAGE inhibitor, this thesis has shown that inhibition of TGF-β signaling 
via CWHM 12, also suggesting that mediating TGF-β signaling as a host directed therapy has the 
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potential of enhancing Mtb control.  If RAGE and TGF-β inhibitors provide synergistic effects 
promoting Mtb control, it is also important to also contemplate the potential off target effects that 
it may have in addition to being protective.  
Currently, the diagnostic method for TB is an automated PCR assay that detects mycobacteria in 
sputum expectorated by patients. Due to limited access, the most common method used is a 
sputum-based microscopy to identify Mtb. Although this is a good method it solely identifies 
individuals with ATB. Therefore, new non-sputum based screening tool for identifying individuals 
with ATB is required so that they can be prioritized for clinical investigation and treatment. The 
human data presented in this thesis demonstrate that S100A8/A9, CXCL-1 and CXCL-10 serum 
protein levels are able to differentiate between ATB and HC, and although less effective can also 
discriminate between ATB and QFT+ LTBI. Thus, further validation of the use of S100A8/A9, 
CXCL-1, and CXCL-10 in different geographical cohorts and in treatment failure and relapse 
studies will be useful and timely. In addition to assessing geographical cohorts, it is necessary to 
determine the specificity and sensitivity is amongst other acute bacterial infections that are 
prevalent in those areas. It also would be beneficial to determine whether S100A8/A9, CXCL-1 
and CXCL-10 is a valid biomarker for individual who are HIV+.  
In summary, the studies within this thesis have suggested and described a pivotal role for 
S100A8/A9 proteins and TGF-β in mediating TB pathogenesis and its association with lung 
neutrophil accumulation. Additionally, experimental studies targeting the S100A8/A9 and TGF-β 
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